



14.10.2023 .

	(/)		400
A06.30.002.001			1000
	(, , ,)		200
	(, ,)		500
A06.30.002.002			1000
A06.30.002			500
B01.039.001	(,) -		1300
B01.039.002	(,) -		1100
A06.23.004	/		2600
A06.23.005.006	/		8700
A06.08.007	,		2600
A06.08.007.004			8700
A06.25.003			2600
A06.25.003.002			8700
A06.26.006			2600
A06.26.006.001			8700
A06.23.004.007			8700
A06.08.007.002			8700
			8700
A06.08.009.002			8700
A06.09.005			2600
A06.09.005.002			8700
A06.11.004			2600
A06.11.004.001			8700
A06.30.005			3500
A06.30.005.003			8700

A05.22.002.001		6500
A05.26.008.001		7100
A05.08.001		3100
A05.26.008		3100
A05.22.002		3100
A05.04.001	-	5000
A05.30.008		3100

A05.04.001	-	3100
A05.30.008		3100
A05.03.002		3100
A05.03.002		3100
A05.03.002		3100
A05.03.002.001		7100
A05.30.008.001		7100
A05.03.002.001		7100
A05.03.002.001		7100
A05.23.009.010	()	3100
A05.23.009.011	()	7100

	()	14000
A05.30.005		4000
A05.30.007		4000
A05.30.005.001		7100
A05.30.007.001		7100
A05.22.001	-	4000
A05.22.001.001	-	7100
A05.14.002		7100
A05.15.001		3500
A05.15.002		4000
A05.28.002		3100

A05.30.004.001		7100
A05.30.004		4000
A05.21.001		4000
	()+	7000
A05.21.001.001	c	7100

A05.30.004.001		7100
A05.30.004		4000

A05.30.004	() (, ,)	4000
------------	-------------	------

A05.04.001	(, ,) , , ,	3500
------------	---------------	------

A05.30.011.002			3500
A05.30.012.002			3500
A05.30.010			4000
A05.01.002			4000
A05.01.001			7100
A05.30.010.001			7100
A05.03.002	+	+	7000
	+		5000
	+		5000
	+		5000
	:	+	7000
	+	+	7000
	+		4500
	+		4500
		+	5000
A05.03.002		+	4500
		+	4500
	+		7000
	+		4500
		+	4500
		+	5000
A06.08.003			1000
			1000
	2		1000
A06.08.003.002			1000
A06.08.003.002			1000
A06.03.005		,	1000
A06.03.056			1000
A06.04.001		-	1000
A06.26.001			1000
A06.07.008			1000
A06.07.009			1000
A06.25.002			1000
A06.25.002.001			1000
A06.03.010			1000
	()	2000
A06.03.013			1000
A06.03.019			2000

A06.03.014			2000
-			
A06.03.015		2	1000
		3	2000
A06.03.017			1000
A06.03.016			2000
A06.03.017.001			1000
A06.03.017.002			1000
-			
A06.04.013			1000
		2	1000
A06.04.010			1000
A06.03.028			1000
A06.04.003			1000
A06.03.029			1000
A06.04.004			1000
A06.03.026			1000
A06.03.032			1000
		2	1000
A06.03.035		1	1000
A06.03.021			1000
A06.03.030			1000
A06.03.027			1000
A06.03.031			1000
A06.03.033			1000
-			
A06.04.005			1000
		2	(1)
		2	1000
A06.03.042			1000
		2	1000
A06.04.012			1000
A06.03.053		2	1000
			1000
A06.03.050			1000
			1000
		2	2000
A06.03.036			1000
A06.03.048			1000
A06.03.054			1000
A06.03.055		1	1000
A06.04.011			1000
A06.03.043			1000
A06.03.045			1000
A06.03.046			1000

A06.03.049						1000
A06.03.051						1000
A06.03.052		1				1000
A06.03.053.001						1000
A06.30.004.001						1000
						3000
A06.28.001						1000
		2				1000
A06.28.002						3100
		1	()			1000
		2				1000
A06.03.023		()				1000
A06.03.024						1000
A06.04.014		-				1000
A06.03.022						1000
A06.09.007						1000
		-				1000
						1000
		1				1000
		2				1000
A06.20.004						1000
A06.20.004		2				1500
	c		(1	2-)	1500
	c		(2	2-)	2500
A06.20.004.002						1500
A06.20.008						1000
B01.023.001	(,)	-				1300
B01.023.002	(,)	-				1100
B01.023.001	(,)					2500
	(-)					
B01.023.001	(,)	-	()	60		2300
B01.023.002	(,)	-	()	30		2100
A11.02.002	(1)					2500
A22.30.015	(1)					1000
A11.02.002						29900
A25.24.001.002						19500
A25.24.001.002						8900
A11.01.002		225	()			24000

A11.24.001			2000
A11.02.002			1500
A11.02.002			1500
A11.02.002	()	1500

B01.047.001	(,)	-	1300
B01.047.002	(,)	-	1100
	()			1200
	()			2500

B01.031.001	()			1300		
B01.031.002	()			1100		
B01.031.001	()			2000		
B01.031.002	()			2000		
B01.031.001					1300		
B01.031.001	()			1300		
B01.031.001			-1	(,)	1500
B01.031.001	()			800		
B01.031.001	/	()		700		
B01.031.001	(:	,)	800		
B01.031.001			18	(095/)	800
-	095/				800		
B01.031.001					800		
B01.031.001	-	(076/)	2000		
B01.031.001		(079/)??	800		

B01.029.001	(,)	-	1300
B01.029.002	(,)	-	1100

A02.26.015	-	()	200
A12.26.016				150
A03.26.010		()	400
A03.26.010		()	400
A02.26.015				200
A02.26.015	()		400
A02.26.015	()		200

B01.057.001	(,)	-	1300
B01.057.002	(,)	-	1100

B01.057.001	(,)	-	(800
B01.057.002	(,)		()	800
A16.01.012.001				1900
A16.01.012				1200
A16.01.002				1500
A16.01.002				1200
A16.01.012.001	()	()	2	1800
A16.01.011	()			1000
A16.01.027				2600
A16.30.060				1800
A16.01.009	()			1500
A16.30.069	()			500
A16.01.001				1000
A11.04.005				1000
A16.01.012.001				1300
A11.30.024				1100
A16.01.012.001	()	()	1	1300
A16.01.008.001				2100
A16.01.004			(700
A16.01.004			()	2000
A15.01.001				400
A15.01.002				500
A11.01.001	()			400
A16.30.076				1400
A16.01.028	()			500
A16.01.016	(0,5-1 ,1)			1300
A16.01.016	(1-3 ,1)			1500
A16.01.016	(3-5 ,1)			1900
A16.01.017			(1-3 ,1)	1300
A16.01.017			(3-5 ,1)	1500
A16.01.017			(3-5 ,1)	1900
A16.01.017			(5 ,1)	2400
				500
A16.01.018	(, , 0,5-1 -1)		-	1300
A16.01.018	(, , 1-3 -1)		-	1500
B01.003.004.005				500
B01.003.004.001				500
A11.01.001	()			400
A16.01.003				2000
A16.30.032		1	-3 1	1300
A16.30.032		3	-5 1	1900
A16.01.018	(, , 3 -5 1)		-	1900

A16.30.007.001				19000	
A16.30.043.002				14800	
A16.30.043.003				26000	
A16.14.018.003				11000	
A16.30.004.003		()	42300	
				56400	
A16.30.004.007				65000	
A16.30.004.016				55000	
A16.01.018			-	6500	
(5	1)		
A16.30.001.002			-	35000	
A16.30.002.002				35000	
A16.30.001		()	23100	
A16.30.002		()	20000	
A16.14.009.002				35000	
A16.19.018			()	15000
A16.30.032		5	1	6500	
A16.30.004.004			()	46000
A16.30.004.010			1	40000	
A16.30.004.010			2	55000	
A16.30.004.010			3	70000	
		(2200	
A04.12.005.003			()	1500
-		(+)	2400
-		(+)	2800
				1500	
A04.12.001.004			-	800	
A04.12.001.004				800	
A04.12.001.001				1400	
A04.12.002.002				1400	
A04.12.002.001				2000	
A04.12.002				1900	
A04.12.002.003				1000	
A04.12.001				1000	
		()	+	2000
A04.12.014				900	
A04.12.001.006			()	1800

	()+		2800
A04.12.022			1400
A04.12.001.002			700
A04.12.003			1100
A04.22.001			500
			800
A04.22.001.001			900
			800
A04.16.001	(, , , , ,)		1100
	(,) , , , , , , ,		2000
A04.06.001			500
A04.15.001			600
A04.28.002.005			600
A04.14.001			800
A04.14.002			500
A04.14.002.001			700
A04.18.001	()		800
A04.28.002.001			800
A04.22.002			500
A04.28.001			800
A04.28.002.001			700
A04.28.002.003			500
A04.28.003			800
A04.10.002	(+)		1800
A04.01.001	()		750
A04.09.001			600
A04.28.002.003	()		1100
A04.06.002			800
A04.06.002			800
A04.06.002			800
A04.06.002	/		800
A04.06.002			800
A04.06.002			800
A04.06.002	, / , , , , ,		2000
A04.21.001			1000
	()		1200

	()+ +	1400
A04.21.001.001	+	1100
	+	1300
A04.20.002		950
		1100
A04.30.010	()	950
A04.30.001	()	1000
A04.30.001.001	()	1000
A04.30.001.007	III	1500
A04.12.024.003	()	1000
	II-III)	
A04.04.001	()	700
A04.20.003	()	700
A04.20.003	()	400
A04.20.001.004	(-)	500
A04.30.001.002	4D (26 , ,1)	2500
A04.30.001	II	1200
A04.30.001.002	3D	1350
A04.30.001.001	()	1500
A04.12.024.003	() ()	1500
	II-III)	
A04.30.001.006	- , , , ,	2000
(II)		
A04.30.001.008	III	2000
A04.30.001.002	4D ,1)	3500
	(26 , , , ,1)	
A04.30.001.002	3D	2000
A11.06.001.001		900
A11.20.010.003		900
A11.22.002.001		900
A11.30.024.001		900
A04.04.001	()1	900
A04.04.001	()1	700
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	600
A04.04.002	()	600

B03.037.001		500
A05.10.006		500
A02.12.002.001		1200
A05.10.008	24	2000
+	24	2200
A12.10.001	(+)	750
		750
A05.23.001		1100
		150
	: ,) , (420
	: ,) (« »	590
	()()	190
	:	3230
	:	2020
	:	1100
B03.005.006	() ,	770
	()	2510
	(HIV, Syphilis, Hepatitis B, C)	1400
	IgG	470
	IgG	470
(Coronavirus disease 2019, COVID-19)		
	SARS-CoV-2 () , IgG, (Anti-SARS-CoV-2 (nucleocapsid protein), IgG, Abbott)	690
	SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)	690
	SARS-CoV-2, IgM IgG (. . . IgG - Abbott)	1290
	(S) SARS-CoV-2, IgG (), . . . (anti-SARS-CoV-2 S (spike) protein antibody, IgG, qual., including post-vaccination)	890
	SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)	690
	SARS CoV-2 (S- , RBD), IgG, -	1290
	SARS CoV-2 (S- , RBD), IgG, Abbott	1290
	SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
	SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
	()	
A	IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)	490

MICROBIOECENOSIS, Screening (PCR Panel Femoflor Screen))	(UROGENITAL TRACT	1850
Cells, 4 Types (6, 11, 16, 18) Screening)	4 : 6, 11, 16, 18 + (HPV DNA, Scrape of Urogenital Epithelial	550
RPR – nticardioliopin est)	(Syphilis RPR (Rapid Plasma Reagins),	210
A09.05.007 (Fe)		190
()) (Unsaturated Iron Binding Capacity, UIBC)	(,	190
/ /	(+ /Potassium, Na+ /Sodium, I- /Chloride, Serum)	250
A09.05.127 (g)	(Magnesium (Mg), Serum)	230
A09.05.076 (Ferritin)		460
A09.05.009 - () (C-Reactive Protein, CRP)		310
A09.05.008 () (Transferrin)		440
25-OH D (25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)		1920
A09.05.083 HbA1 (HbA1 , Glycated Hemoglobin, GHB)		460
A09.05.023		130
A09.05.214 (Homocysteine)		1290
A09.05.010 (Protein Total)		150
A09.05.011 (Albumin)		210
A09.05.130 () (Prostate-Specific Antigen Total, PSA Total)		440
-125 (125) (Carbohydrate Antigen -125, Cancer Antigen -125)		580
SCC () (Squamous Cell Carcinoma Antigen, SCCA,SCCAg)		2260
A09.05.020		150
A09.05.018 (Uric cid)		150
A09.05.017		150
A09.05.025 () (Triglycerides)		190
A09.05.004		200
A09.05.028 ()) (Low-Density Lipoprotein Cholesterol, LDL Cholesterol)		150
A09.05.026 () (Cholesterol Total)		190
A09.05.021		150
A09.05.039 (, L- , +) (Lactate Dehydrogenase, LDH)		150
A09.05.046 () (Alkaline Phosphatase, ALP		150

A09.05.063	(4)		350
A09.05.065	()		330
	(- ,) (Anti-thyroid Peroxidase Antibodies, Antimicrosomal Antibodies, TPO Antibodies, TPOAb, Anti-TPO)		390
A09.05.061	(3) (Free Triiodothyronine, FT3)		350
	(2) (Estradiol, E2)		350
A09.05.056	(Insulin)		490
	: (), (),		670
HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)			
A09.05.087	(Prolactin)		350
A09.05.132	() (Follicle Stimulating Hormone, FSH)		350
A09.05.131	() (Luteinizing Hormone, LH)		350
A09.05.066	(,) (Growth Hormone, GH)		470
A09.05.065	()		330
A09.05.078	(Testosterone)		350
	- (-S04, Dehydroepiandrosterone sulfate, DHEA-S)		350
	(2) (Estradiol, E2)		350
	(Calcitonin)		860
B03.016.006	() (Complete Urinalysis, Microscopic Examination)		230
B03.016.014	(Nechiporenko's Urine Test)		230
A09.28.027	(- ,) (Amylase, 24-Hour or Timed Urine)		230
	: (Lipid Profile: Extended)		2640
B03.016.005	: (Lipid Profile: Screening)		700
A12.05.005	(Blood Group, 0)		230
A12.05.006	- (-) (Rh-factor, Rh)		230
	,		680
	(Zn) (Zinc (Zn), Serum)		250
A12.05.027	() (Prothrombin, Prothrombin Time, PT, International Normalized Ratio, INR)		230
A09.05.051.001 D-	(D-Dimer)		1030

(ThinPrep®)		1200
12	JAK2 ((4390
qualitative)) (Analysis of JAK2 Exon 12 mutations (PCR			
(PCR qualitative))	MPL ((4390
(Analysis of MPL gene mutations, deletions,			
	CALR ((4390
mutations, deletions, insertions, PCR, qualitative)			
(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)			800
A12.20.001			450
A09.05.054.001	E (IgE,	390
(Immunoglobulin Total, IgE Total)			
B01.058.001	() -	1300
B01.058.002	() -	1100
B01.001.001	() -	1500
B01.001.002	() -	1200
B01.001.002	() -	800
A11.20.011			1500
A11.20.014			1500
A11.20.008			5400
A11.20.008.001			2900
A11.20.005			300
A11.20.002			300
A11.20.002			450
A11.20.003			800
A03.20.001			1000
A11.20.015			500
A16.20.036			2100
A08.20.004	() (1400
A11.20.015			500
A14.20.002			900
(
A16.20.036.001			7500
A16.20.061.001			40500
A16.20.061.001			35000

A16.20.038			39000
A16.20.016			39900
A16.20.017.001			34900
A16.20.004.001			30900
A16.20.003.001	-		36900
A16.20.041.001			29900
A16.20.001.001	()		34900
A16.20.001.001	()		37900
A16.20.003.001			30900
A16.20.010.001	()		73900
A16.20.010.001	2 ()		75900
A16.20.010.003	()	1	74900
A16.20.010.003	()	2	84900
A16.20.010	()		58900
A16.20.011.001	()		83900
A16.20.011.001	()		94900
A16.20.011.002	()		76900
A16.20.011.002	2 ()		87900
A16.20.063			92900
A16.20.033			35900
A16.20.012			77900
A11.20.003			1100
A03.20.003			19000
A16.20.042.003	()		60750
-			
A16.20.035.001	()		58900
A16.20.035.001	()		39900
A16.20.035.001	()		61900
A16.20.028.002			20900
A16.20.028.003			20900
A16.20.083			38900
A16.20.023			31900
A16.20.065			21900
A16.20.063.018			21900
A03.20.003			17000
A03.20.003.001	1		26900
A03.20.003.001	2		33900
A03.20.003.001	3		39900
A16.20.066			4100

A11.20.018	(2900
A16.20.059)	950
A16.20.059.001		3900
A16.20.036		5900
A16.20.091.001		2800
A11.20.008.001		2000
A11.20.008.002		2700
A16.20.006		42000
A16.20.007		28900
A16.20.098	(1	27770
A16.20.098	(2	41000
+)		
A16.20.083		46000
A16.20.029		27770
A16.20.024		63000
A16.20.028.005	(1	49000
A16.20.028.005	(2	60000
A16.20.019	+	120000
A11.01.013		10200
A11.01.013		14900
A11.01.013		26900
(7 +),		1350
(Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*		
(4 +): Chlamydia trachomatis,		930
Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium,		
(Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)		
+ , o 16 18	(HPV DNA, Scrape of	350
Urogenital Epithelial Cells, 2 Types (16, 18))		
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 +	14 :	350
(HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))		
() 14 : 16,		900
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 +		
(HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)		
(Neisseria gonorrhoeae, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Neisseria gonorrhoeae,),		900
(GC, Neisseria gonorrhoeae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		
(Bacterial Vaginosis, BV)		1540
(Chlamydia trachomatis),		250
(Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*		
A08.20.017.002		1200
(, ThinPrep®)		
A08.20.004		600

		2200
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))		2780
APS) (), (Antiphospholipid Syndrome,		3570
(Genitourinary Tract Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*		1160
(Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*		1500
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)		570
MICROBIOCENOSIS (PCR Panel Femoflor 16)) 16. (UROGENITAL TRACT		2100
		450
(Cytological Examination: Cervix, Pap-test)		1000
(Candidiasis, Screening and Typing)		920
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen)) . (UROGENITAL TRACT		1850
MICROBIOCENOSIS (PCR Panel Femoflor 8)) 8. (UROGENITAL TRACT		1480

B01.053.001 (,) -		1300
B01.053.002 (,) -		1100

A16.28.040 (1)		2100
		10000
A16.28.058		1000
A16.28.052.001		2400
A16.28.072.001		2400
A11.28.008		1600
A11.28.006.001		500
A21.21.001		550
A12.21.003		650
A15.21.001 ()		1000
A03.28.002		3500
A03.28.003 ()		6000
A03.28.001		5000
A16.28.077		5000
A11.28.012		1000
A16.21.015		2300
A16.28.013.001		1000
A06.28.007		5000
A06.28.011		5000
()		10000

B01.015.001	(,) -		1300
B01.015.002	(,) -		1100
B01.008.003	()		1300
B01.008.004	()		1100
A11.02.002	. (1)		260
A11.02.002	. (1)		290
A11.01.003	. 1		2999
A11.01.003	. 2		4999
A11.01.003 PRP-	1 (1)		5000
A11.01.003	mesoline () 2,5 .		2500
A11.01.003	mesoline () 2,5 .		2500
A16.01.024	(PRX-t33)		3750
A16.01.024			2000
A16.01.024			2500
A14.01.008			3000
			2000
B01.028.001	(,) -		1300
B01.028.002	(,) -		1100
B01.028.002	() -		800
A11.01.014			200
A12.25.001			1000
A11.07.004	()		1500
A11.08.001	()		5000
	()		3000
A11.25.006	()		3000
			350
			200
A11.08.019			600
A16.01.012	(, ,) -		3000
A16.08.054			1500
A16.08.010.001	() (RadioSURG)		10000
A11.08.007			1000
			100
A03.25.003			300
A22.30.033			2200
A11.08.022	(-) - (1)		2500
A11.08.022	(-) - (2)		3500

A21.25.002			
A11.07.022			
)		(,
A16.01.004			
A15.01.002			
A16.08.006.001	(1)	
,	-		
A12.25.006			
A11.08.021.001			
A16.08.016			
A16.25.007	(1)	
A11.08.004			
A16.08.023	(1)	
A16.08.023	(2)	
-			
A11.25.003.001			
A16.01.017.001	-	1	.(1
)			
A16.01.017.001	-	1 3	.(1
)			
A16.25.008			
A16.08.011	,	,	
()		
()		
()		
B01.003.004.004			
B01.003.004.005	(I)	
B01.003.004.005	(II)	
B01.003.004.005	(III)	
()		
()		
()		
A11.08.020			
()		
A03.25.001			
A16.08.012			
A16.01.017.001	-	1	.(1
)			
A16.01.017.001	-	1 3	.(1
)			

250
300
800
400
1000
800
2000
2000
300
700
700
600
500
1300
1800
3000
250
350
600
3300
3500
1500
1200
500
900
1400
1200
300
300
500
700
900
200
200
200
200
6000
400
800
700
300
3800
4000

				4000
A16.08.009.001	-1		:1	10000
A16.08.009.001	-1		:2	20000
A16.08.009.001	-1		:3	30000
A16.08.010.001	():1	10000
A16.08.010.001	():2	15000
A16.08.010.001	():3	20000
A16.25.020				13000
A16.25.011	()	1500
A16.25.011	()	2000
B01.003.004.001	()	1000
			:1	12000
			:2	15000
			:3	20000
				700
				1000
A16.08.013	():1	18000
A16.08.013	():2	24000
A16.08.013	():3	29000
A16.08.001	()1	35500
				1000
A16.08.014		1		10000
A15.03.003				1500
				7000
A16.08.012				3500
A16.08.017.001		1		30000
A16.08.017.001		2		37000
A16.08.017.001		3		42000
A16.08.035				35000
A16.08.002		1		28500
A16.08.002		2		38000
A16.08.001		3		42500
A16.08.001	()2	37500
A16.08.001	()3	42500
				5000
A16.08.064		1		18500
A16.08.064		2		23500
A16.08.064		3		28500
A16.08.014		2		15000
A16.08.014		3		25000
				710
				2200

A04.12.014		900
	()	1300
A04.12.003.001 ()		900
A04.12.002.002		1100
A04.12.002.001		2000
A04.12.002		1800
A04.12.002.003		1000
A04.12.001		1000
A04.12.001.001		1100
A04.12.001.002		600
	()	1500
A04.22.001		500
		700
		800
A04.16.001	(, , , ,)	1100
	(, ,)	1800
A04.14.001		700
A04.14.002		500
A04.14.002.001		650
A04.06.001		500
A04.15.001		500
A04.18.001		500
A04.28.002.001		800
A04.22.002		400
A04.28.001		700
A04.28.002.001		600
A04.28.002.005		600
A04.28.002.003		500
A04.28.003		700
A04.10.002	(+)	1650
A04.01.001	()	750
A04.09.001		600
A04.06.003		600
A04.06.002		800
A04.06.002		800
A04.06.002		600
A04.06.002	/	600

A04.06.002			600
A04.06.002			600
A04.06.002	, /	, , ,	1900
A04.21.001			700
A04.20.001	()		850
A04.20.002		()	850
A04.20.002.001 ()			950
A04.20.002	()		700
A04.23.001 (+)	()		900
A04.23.001	()	()	700
A04.03.001	1		700
A04.07.002			600
A04.08.001	(4-5)		500
A04.04.001.001	(1)		600
A04.03.001			600
A04.04.001	(- / -)		450
B01.059.001	(,) -		1200
B01.059.002	(,) -		1100
A03.08.004.002			6900
()			
A03.16.001	()		2300
A11.16.002	- ()		900
	IgA Helicobacter pylori)		850
A26.19.098	Helicobacter pylori ()		870
A11.16.002	/		1040
	Helicobacter pylori IgG (-)		3220
A11.16.002	()		400
A03.16.001.005	()		2900
			2000
A11.16.001	()		400
A11.16.003	()		400
A03.16.001.001			4900
A03.16.001.004			2400
A11.16.010			1100
A16.12.020.002			4900
A16.16.041.001			6500
A16.16.041.003			5000
A16.16.048			5000

A03.18.001.001			2600
A03.19.002			1800
A11.18.001	()	400
A11.19.001	()	400
A11.19.002)	(400
A16.18.019.001	(1)	6900
A16.18.019.001	(1 2-)	8100
A16.18.019.001	(2-)	10900
A03.18.002			11900
A03.19.004			3100

A03.09.001			2900
A03.08.001.001	()	2600
A11.07.016.001)	(400
A11.08.003.001	()	400
A11.08.008.001	()	400
A11.08.012.001	()	400
A03.09.002			2900
A03.09.003			3300
A03.16.002			500
A03.30.006.001			2900
A11.09.008			400

()		1300
()		1100

B01.027.001	(,)	-		1300
B01.027.002	(,)	-		1100

(60)		2100
-----	---	--	------

Check-Up	45				11499
Check-Up	40				12799
Check-Up	45				15599
Check-Up	40				16999
Check-Up (-)"		"	40		7100
Check-Up (-)"		"	40		8800
")	" (;	;	2990
")	" (+		1600

	+		+		+		7500		
B01.004.001	(,)	-			1300		
B01.004.002	(,)	-			1100		
A11.12.003.001	()				400		
A11.12.003				()	250		
A11.01.002							170		
A11.02.002							200		
A11.16.010							1100		
A11.12.003.001	()	2	.		200		
A11.12.003.001	()	8			100		
A11.12.003.001	()	5			100		
A11.12.003.001	()	30	/1	(1)	50	
A11.12.003.001	()	5	/	100	(1)	450
A11.02.002				5	/	(1)	50	
A11.02.002				50	/	(1)	50	
A11.12.003.001	()	10			230		
A11.12.003.001	()	5			300		
A11.02.002						2	.	200	
A11.12.003.001	()	10	(1	+	.	-)	120
A11.12.003						2.0	(1)	30
A11.12.003				1.0	(1)		15	
A11.12.003.001	()	1,5%	200		200		
A11.12.030				2			()	25
				5	/			150	
	()				1300		
	()				1100		
B01.008.001	(,)	-			1300		
B01.008.002	(,)	-			1100		
B01.023.003				-		(1200	
3-)			

B01.058.006	-	(1200
3-)			
B01.047.009	-	(1200
3-)			

B01.003.001	()	-	-	1300
B01.003.002	()	-	-	950

B01.003.004.009				()	3200	
B01.003.004.009						4200	
B01.003.004.009				()	5300	
B01.003.004.009				(30)	5500
B01.003.004.009				(1)	10000
B01.003.004.012					30	6500	
B01.003.004.012					1	12000	
B01.003.004.007				(1)	12000
B01.003.004.007				(2)	13000
B01.003.004.008	-				1	11900	
B01.003.004.008	-				2-	16000	
B01.003.004.010				(1)	13000
B01.003.004.010				(2)	15000
B01.003.004.009				(2-)	13500
B01.003.004.009				(2-)	15000
B01.003.004.007				(2)	14000
B01.003.004.006				(30)	8000
B01.003.004.006				(1)	12000
B01.003.004.006				(2)	13000
B01.003.004.006				(2)	15000
B01.003.004.008	-			(30)	7000
B01.003.004.008	-			(2)	15000
B01.003.004.010				(30)	7000
B01.003.004.010				(2-)	17000
B01.003.004.012				(30)	7000
B01.003.004.012				(1)	12000
B01.003.004.012				(2)	13000
B01.003.004.012				(2)	16000
B01.003.004.011				(30)	6000
B01.003.004.011				(1)	11000
B01.003.004.011				(2)	15000
B01.003.004.011				(2)	16000

	/			(1	-)	()	5000
										5000
B01.003.003	-			-						10000

		3000
B01.001.007	- - ' (2500
)		
(,) -		1300
(,) -		1100
(,1)		6500
()1		3100
()1		1500
()2		2100
		15000
1) (2100
		5900
		15000
		1800
		1100
		600
		600
/		700
		6100
		10000
1		8600
2		11600
3		15100
(1)		7000
A14.19.002		700
(,1)1		10100
(,1)2		15100
(/)1		11900
(/)2		15900
)1 (6300
)2 (9300
()1		19000
()2		23000
()3		29000
()1		27000
()2		31900
()3		45100
1		20100
2		24100

	3		37100
	"A"	"M",	"A1" "B1"
	"A"	"M", ("A1" "B1"
	"B"	"BE",	"B1" ()
	"B"	"BE",	"B1" ()
B01.050.001	(,)	- -	1300
B01.050.002	(,)	- -	1100
A11.04.003			1100
A11.04.004			1200
A15.02.001			500
A15.03.001			500
A15.03.003			700
A15.03.003.002			600
A15.03.007			600
A15.03.009			700
A15.03.010	()		500
A15.03.010.001			600
A15.04.001	()		700
A16.02.007		()	29900
A16.02.008		()	29900
A16.02.009			26000
A16.03.034			2600
A16.04.003			23000
A16.04.018			3100
A16.30.032			1300
A16.30.032			1500
A16.30.032			1900
A16.30.032			2400
			150
		IgG4-	1670
	(Diagnosis of Autoimmune Pancreatitis and other IgG4-Related Diseases)		
	Ig () (Anti- ndomysial antibodies, Anti-EMA, Ig)		1300
	IgG () (Anti-Sacch romyces Cerevisiae Antibodies, ASCA, IgG)		1120

(IKBKG, . . . (Bloch-Sulzberger Syndrome, Familial Incontinentia Pigmenti, Gene IKBKG, Freq. Mut.)	4680
GJB2	10240
NS3, NS5A NS5B	11670
(3) RAB27A, . (Griscelli Syndrome, Gene RAB27A, Mut.)	19480
C1NH, . (Hereditary Angioedema Type I, Gene C1NH, Mut.)	27250
(22, . (Charcot-Marie-Tooth Disease Type 1B, Gene 22, Mut.)	15930
HRAS, . (Costello Syndrome, Gene HRAS, Mut.)	6510
RMRP, . (Metaphyseal Chondrodysplasia, McKusick Type, Gene RMRP, Mut.)	6510
MEFV, . (Familial Mediterranean Fever, FMF, Gene MEFV, Mut.)	37750
SBDS1, . . . (Shwachman-Diamond Syndrome, Gene SBDS1, Freq. Mut.)	6510
HLA-A29	3000
ACVR1, « . » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, without Hot-Point Mut.)	27250
EDNRB, . (Waardenburg-Shah Syndrome, Gene EDNRB, Mut.)	27250
ERCC6, . (Cockayne Syndrome, Gene ERCC6, Mut.)	85530
SLC26A2, . (Diastrophic Dysplasia, Gene SLC26A2, Mut.)	23370
B1. ROR2, . (Brachydactyly Type B1, Gene ROR2, Mut.)	12970
(Gene GLI3, Mut.)	69990
GLI3, . (Greig Syndrome, Gene GLI3, Mut.)	8100
(EGR2, . (Charcot-Marie-Tooth Disease Type 1B, Gene EGR2, Mut.)	15600
7 9 FGFR2, . (Crouzon Syndrome, Exons 7, 9 Gene FGFR2, Mut.)	9090
- a - a (ENG, . (Rendu-Osler-Weber Disease, Gene ENG, Mut.)	35020
NDP, . (Familial Exudative Vitreoretinopathy, FEVR, Gene NDP, Mut.)	10240
LMNA, . (Familial Partial Lipodystrophy 2, Gene LMNA, Mut.)	38910
(LMX1B, . (Nail-Patella Syndrome, NPS, Onychoosteodysplasia, Gene LMX1B, Mut.)	27250
SGCE, . (Myoclonic Dystonia, Gene SGCE, Mut.)	46680
ATP7B, . . (Wilson Disease, Gene ATP7B, Freq. Mut.)	9350
, NGF . (Hereditary Sensory and Autonomic olynuropathy, Gene NGF, Mut.)	15600
« » ALMS1, « . » . . (Alstrom syndrome, Gene ALMS1, Hot-Point Mut.)	12970
(TCOF1, . (Treacher-Collins Syndrome, Franceschetti-Klein Syndrome, Mandibulofacial Dysostosis without Limb Anomalies, Gene TCOF1, Mut.)	85530
GJB3, . (Erythrokeratoderma, Gene GJB3, Mut.)	10240
, GLA, .	9200
« » TRPV4, « . » . . (Distal Spinal Muscular Atrophy Congenital Non-Progressive, Gene TRPV4, Hot-Point Mut.)	12970
SLC22A5, . (Systemic Primary Carnitine Deficiency, SPCD, Carnitine Deficiency Systemic Primary, CDSP, Gene SLC22A5, Mut.)	38910
FXN, . . (Friedrich A taxia, Gene FXN, Freq. Mut.)	8200

EMG1, . (Bowen Conradi Syndrome, BCS, Gene EMG1, Mut.)	15600
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 3 Freq. Mut.)	4680
Syndrome, Gene BCS1L, Mut.)	15930
TWIST1, . (Saethre-Chotzen Syndrome, Gene TWIST1, Mut.)	13560
GDAP, . (Charcot-Marie-Tooth Disease Type 2A1, Gene GDAP, Mut.)	23370
COMP, . . (Pseudoachondroplasia, Gene COMP, Freq. Mut.)	6200
Gene NPHS1, Mut.)	69990
FGFR3, . . (Achondroplasia, Gene FGFR3, Freq. Mut.)	10960
NLRP3 . (Familial Cold Autoinflammatory Syndrome, FCAS, Gene NLRP3, Mut.)	46680
O, . (Charcot-Marie-Tooth Disease Type 1B, Gene O, Mut.)	15600
DLL3, . (Spondylocostal Dysostosis, Gene DLL3, Mut.)	27250
NPHP1, . (Nephronophthisis 1, NPHP1, Gene NPHP1, Mut.)	15460
FHL1, . (Emery-Dreifuss Muscular Dystrophy, Gene FHL1, Mut.)	31140
ANKH, . (Chondrocalcinosis, Calcium Pyrophosphate Dihydrate, CPPD, Gene ANKH, Mut.)	46680
MULIBRAY. TRIM37, . (Muscle-Liver-Brain-Eye, Gene TRIM37, Mut.)	9090
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 12 Freq. Mut.)	12970
ATXN7, . . (Spinocerebellar Ataxia, Gene ATXN7 Freq. Mut.)	4680
IGHMBP2, . (Distal Spinal Muscular Atrophy 1, DSMA1, Gene IGHMBP2, Mut.)	58330
RP2, . (Retinitis Pigmentosa, Gene RP2, Mut.)	19480
Syndrome, Type VI, Gene PLOD, Freq. Mut.)	9350
(Aarskog-Scott Syndrome, Faciodigitogenital Syndrome, Faciogenital Dysplasia, Gene FGD1, Mut.)	57020
Spinal and Bulbar Muscular Atrophy, Gene AR, Freq. Mut.)	4680
PCSK9	10620
(X)	5790
/ , FMR1, . .	3100
GLI3, . (Pallister-Hall Syndrome, Gene GLI3, Mut.)	69990
9 FGFR2, . (Antley-Bixler Syndrome, ABS, Exon 9 Gene FGFR2, Mut.)	6510
7, 9 FGFR2 7A FGFR1, . (Pfeiffer Syndrome, Exons 7, 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	12970
/	10730
(Familial Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Freq. Mut.)	4680
TNFRSF6, . (Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Mut.)	31140
5, 8 RET, . (Familial Meddulary Thyroid Cancer, Exons 5, 8 Gene RET, Mut.)	9090
SBDS, . (Shwachman-Diamond Syndrome, Gene SBDS, Mut.)	19480
KCNJ2, . (Andersen-Tawil Syndrome, Gene KCNJ2, Mut.)	15930
(1-)	10960
ABCA4, . . (Stargardt Disease 1, STGD1, Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut.)	10960

CHM, . (Choroideremia, CHM, Gene CHM, Mut.)	58330
	6900
WWS, Gene FKRP, Mut.)	13560
Syndrome with Acanthosis Nigrificans, CAN, Exon 10 Gene FGFR3, Mut.)	6510
Agammaglobulinemia, XLA, Gene BTK, Mut.)	69990
D- ().	85530
PHEX, . (Hypophosphatemic Vitamin D-Resistant Rickets, Gene PHEX, Mut.)	23370
Progressive, Gene GRN, Mut.)	15600
XK, . (McLeod Syndrome, Gene XK, Mut.)	38910
(Testicular Feminization Syndrome, Gene AR, Mut.)	31140
EDA, . (Anhidrotic	23370
Ectodermal Dysplasia, Gene EDA, Mut.)	15460
UPK3A, . (Renal Hypodysplasia, Aplasia 1, Gene	9090
UPK3A, Mut.)	19480
PAH, . . (Phenylketonuria, PKU, Gene PAH, Freq.	4380
Mut.)	46680
« » OPA1,	6200
« » . . (Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia And	4680
Neuropathy, Gene OPA1, Hot-Point Mut.)	19220
ELA2, . (Neutropenia Severe Congenital 1 Autosomal	4680
Dominant, SCN1, Gene ELA2, Mut.)	9090
APOB100	38910
(Congenital Insensitivity To Pain With Anhidrosis, CIPA, Gene NTRK1, Mut.)	27250
NTRK1, .	58330
Epiphyseal Dysplasia, MED, Gene COMP, Freq. Mut.)	27250
COMP, . . (Multiple	9090
PHOX2B, . . (Congenital Central Hypoventilation Syndrome, CCHS, Gene PHOX2B, Freq. Mut.)	38910
(Genes CFTR, GJB2, PAH, SMN))	27250
(CFTR, GJB2, PAH, SMN) (Main Hereditary Diseases	58330
DMPK, . . (Myotonic Dystrophy 1,	27250
Gene DMPK, Freq. Mut.)	9090
DMPK, . . (Myotonic Dystrophy 1,	38910
GJB1, . (Charcot-Marie-Tooth Disease Type 1B, Gene GJB1, Mut.)	27250
TGM1, . (Autosomal Recessive	58330
ongenital Ichthyosis, ARCI 1, All Known Mutations, Gene TGM1, Mut.)	27250
V. BSCL2, . (Distal Hereditary	9090
Motor Neuropathy, DHMN, Gene BSCL2, Mut.)	21400
ZEB2, . (Mowat-Wilson Syndrome, Gene ZEB2,	13560
Mut.)	9090
PRPS1, .	27250
(Phosphoribosylpyrophosphate Synthetase Superactivity, PRS Superactivity, Gene PRPS1, Mut.)	9090
(Albinism oculocutaneous, Hermansky-Pudlak type, Gene HPS1, Freq. Mut.)	21400
HPS1, . .	13560
/	9090
(Klippel-Feil Syndrome, Gene GDF6, Mut.)	13560
GDF6, .	9090
(Craniometaphyseal Dysplasia, Gene ANKH, Hot-Point Mut.)	38910
ANKH, « » .	38910
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene TGM1, Mut.)	13560
TGM1, .	23370
PRNP, . (Creutzfeldt-Jakob Disease, Gene	6900
PRNP, Mut.)	23370
CRYBA4, . (Microphthalmia with Cataract,	
Gene CRYBA4, Mut.)	
:	
TNFRSF1A, .	
(TNF-Receptor-Associated Periodic Syndrome, TRAPS, Gene TNFRSF1A, Mut.)	

(). Cerebelloparenchymal Disorder IV, CPD IV, Classic Joubert Syndrome, Joubert Syndrome type A, Joubert-Boltshauser Syndrome, Pure Joubert Syndrome, Gene NPHP1, Mut.)	NPHP1 (Joubert Syndrome,	15460
, CYB5R3 . . (Methemoglobinemia, Gene CYB5R3, Freq. Mut.)		4680
Mut.)	IT15, . . (Chorea Huntington, Gene IT15, Freq.	4680
Syndrome, Type 1, SGBS1, Gene GPC3, Mut.)	GPC3, . (Simpson-Golabi-Behmel	31140
III, Gene OPA3, Mut.)	OPA3, . (3-Methylglutaconic Aciduria Type	10240
- (X-Linked Lymphoproliferative Syndrome, XLP, Gene XIAP, Mut.)	(), XIAP	31140
FMF, Gene MEFV, Freq. Mut.)	MEFV, . . (Familial Mediterranean Fever,	9070
Gene SRY, Mut.)	SRY, . (Disorders Sex Determination,	6510
Dysplasia, Gene GJB6, Mut.)	GJB6, . (Hidrotic Ectodermal	10240
- congenital 1, NYS1 X-Linked, Gene FRMD7, Mut.)	FRMD7, . (X-Linked Nystagmus	46680
Mut.)	ALX4, . (Parietal Foramina, PFM, Gene ALX4,	15600
WAS, Gene WAS, Mut.)	(). WAS, . (Wiskott-Aldrich Syndrome,	27250
, . (Emery-Dreifuss Muscular Dystrophy, X-Linked Gene Emerine, Mut.)		13560
Enteropathica, Gene SLC39A4, Mut.)	SLC39A4, . (Acrodermatitis	31140
22, . (Hereditary Neuropathy with Liability to Pressure Palsies, HNPP, Gene 22, Mut.)	22, Mut.)	15930
. . (Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Freq. Mut.)	(). TCIRG1,	4680
SCN4A, . (Hypokalemic Periodic Paralysis Type 1, Exons 12, 18, 19 Gene SCN4A, Mut.)	12, 18 19 Gene SCN4A, Mut.)	12970
Mut.)	FLG, . (Ichthyosis Vulgaris, Gene FLG, Freq.	9090
	LDLR	11670
-IgD Mut.)	CD40LG, . (Hyper-IgD Syndrome, Gene CD40LG,	38910
IA, Gene TYR, Mut.)	1 . TYR, . (Albinism Oculocutaneous Type	19480
Dystrophy-Dystroglycanopathy, Gene FKR, Freq. Mut.)	FKRP, . . (Muscular	7160
Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut.)	ABCA4, . . (Stargardt Disease 1, STGD1,	10960
(Spondyloepiphyseal Dysplasia Tarda, SEDT, Gene TRAPPC2, Mut.)	(). TRAPPC2, .	15600
Pneumothorax, PSP, Gene FLCN, Mut.)	FLCN, . (Primary Spontaneous	46680
, NBN . . (Nijmegen Breakage Syndrome, NBS, Gene NBN, Freq. Mut.)		4680
PAX3, Mut.)	PAX3, . (Waardenburg Syndrome, WS, Gene	31140
Dystrophy Limb-Girdle Type 2A, Gene FKR, Mut.)	FKRP, . (Muscular	13560
	CTSK, . (Pyknodysostosis, PKND, Gene CTSK, Mut.)	23370
	PAH, . (Phenylketonuria, PKU, Gene PAH, Mut.)	46680
Syndrome, Gene DHCR7, Mut.)	(). DHCR7, . (Smith-Lemli-Opitz	35020
	CFTR, . . (Cystic Fibrosis, Gene CFTR, Freq. Mut.)	15460
		8000
, NOTCH3		11200
Muscular Dystrophy, X-Lyonization, Girls)	(Duchenne	7300
GDF6, Mut.)	GDF6, . (Microphthalmia Isolated 4, Gene	13560

		6900
SPM, Gene FHL1, Mut.)	FHL1, . (Scapulooperoneal Myopathy,	31140
Hemophagocytic Lymphohistiocytosis, Gene PRF1, Mut.)	PRF1, . (Familial	19480
Gene PRNP, Mut.)	PRNP, . (Fatal Familial Insomnia, FFI,	13560
	EXT1, . (Multiple Exostoses, Gene EXT1, Mut.)	46680
Myoclonic Epilepsy 1A Unverricht and Lundborg, Gene CSTB, Freq. Mut.)	CSTB, . . (Progressive	4680
ACVR1, « » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, Hot-Point Mut.)	« »	15600
	2, JPH3, . .	3100
(X-Linked Severe Combined Immunodeficiency, Gene IL2RG, Mut.)	IL2RG, .	15600
	NLRP3 . (Muckle-Wells Syndrome, MWS, Gene NLRP3, Mut.)	46690
Elasticum, Gene ABCC6, Freq. Mut.)	ABCC6, . . (Pseudoxanthoma	6510
	, CYB5R3 . (Methemoglobinemia, Gene CYB5R3, Mut.)	31140
Hypertension 1, PPH1, Gene BMPR2, Mut.)	BMPR2, . (Primary Pulmonary	58330
	FXN, . (Friedrich Ataxia, Gene FXN, Mut.)	19480
	NDP, . (Norrie Disease, Gene NDP, Mut.)	10240
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene LOX12B, Mut.)	(). LOX12B, .	38910
Cardiomyopathy, Gene TNNT2, Mut.)	TNNT2, . (Familial Hypertrophic	46680
(Primary Open Angle Glaucoma 1A, POAG 1A, Gene CYP1B1, Mut.)	(). CYP1B1, .	15930
	FLT4, . (Lymphedema, Gene FLT4, Mut.)	101070
Thrombocytopenia, CAMT, Gene MPL, Mut.)	MPL, . (Congenital Amegakaryocytic	31140
Dystrophy Limb-Girdle Type 2A, Gene SGCB, Mut.)	SGCB, . (Muscular	23370
Hypodysplasia, Aplasia 1, Exons 10, 11, 13, 14, 15 Gene RET, Mut.)	10, 11, 13, 14, 15 RET, . (Renal	19480
Heteroplasia, POH, Gene GNAS, Mut.)	GNAS, . (Progressive Osseous	35020
	(), SOD1, .	6700
	1, TOR1A (DYT1), . .	3100
Syndrome, PPS, Gene IRF6, Mut.)	IRF6, . (Popliteal Pterygium	35020
PTEN, Mut.)	PTEN, . (Lhermitte-Duclos Syndrome, Gene	35020
Dystrophy-Dystroglycanopathy, Gene FKRP, Mut.)	FKRP, . (Muscular	13560
Syndrome, Gene PTEN, Mut.)	PTEN, . (Bannayan-Ruvalcaba-Riley	35020
VHL, . (Autosomal Recessive Erythrocytosis, Gene VHL, Mut.)	(c).	13560
disease type 1A (CMT1A))	, PMP22, (Charcot-Marie-Tooth	15070
Gene ANKH, Mut.)	ANKH, . (Craniometaphyseal Dysplasia,	46680
Disease, CGD, Gene CYBB, Mut.)	CYBB, . (Chronic Granulomatous	46680
Syndrome, Gene LMNA, Mut.)	LMNA, . (Hutchinson-Gilford Progeria	38910
(Crigler-Najjer Syndrome, Gene UGT1, Mut.)	(,). UGT1, .	19480
	MECP2, . (Retts Syndrome, Gene MECP2, Mut.)	19480
	HLA B51	3000

Analysis Gene SRY, Mut)	SRY, . (Disorders Sex Determination,	4680
Dystrophy Limb-Girdle Type 2A, Gene SGCA, Mut)	SGCA, . (Muscular	23370
NEFL, . (Charcot-Marie-Tooth Disease Type 2A1, Gene NEFL, Mut.)	(- -) II.	23370
TNFRSF6, « » . (Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Hot-Point Mut.)	« »	6510
-IgD Syndrome, Gene MVK, Hot-Point Mut.)	MVK, « » . (Hyper-IgD	9090
Fukuyama-Type, Gene FKTN, Mut.)	FKTN, . (Muscular Dystrophy	46680
ESC (-). Syndrome, Goldmann-Favre Syndrome, Gene NR2E3, Mut.)	NR2E3, . (Enhanced S- one	23370
Mut.)	IRF6, . (Van der Woude Syndrome, Gene IRF6,	35020
Mut.)	RS1, . (Retinoschisis 1 X-Linked Juvenile, RS1, Gene RS1,	23370
Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Mut.)	UNC13D, . (Familial	69990
(Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Mut.)	TCIRG1, .	46680
1A Unverricht and Lundborg, Gene CSTB, Mut.)	CSTB, . (Progressive Myoclonic Epilepsy	12970
Mut.)	SH2D1A, . (X-Linked Lymphoproliferative Syndrome, XLP, Gene SH2D1A,	15600
Dystrophy, All Known Mutations, Gene BEST1, Mut.)	BEST1, . (Best Vitelliform Macular	38910
	TWIST1, . (Craniosynostosis Type 2, Gene TWIST1, Mut.)	13560
	MSX2, . (Craniosynostosis Type 2, Gene MSX2, Mut.)	10240
PRNP, . (Spongiform Encephalopathy with Neuropsychiatric Features, Gene PRNP, Mut.)		13560
Mut.)	KRT2, . (Ichthyosis Bullosa Of Siemens, Gene KRT2,	27250
RAB23, . (Carpenter Syndrome, Gene RAB23, Mut.)	(-) .	27250
(Jackson-Weiss Syndrome, JWS, Exon 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	9 FGFR2 7A FGFR1, .	9090
Gene ABCC6, Mut.)	ABCC6, . (Pseudoxanthoma Elasticum,	108840
	, 4, SPAST (SPG4), . .	6300
VHL, . (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Mut.)	(- - -) .	13560
	HLA-Cw6	3000
		5090
Syndrome, AS, Gene FGFR2, Freq. Mut.)	FGFR2, . . (Apert	9350
	(- - - - - LDLR, APOB, PCSK9)	8380
Epiphysial Dysplasia, MED, Gene SLC26A2, Mut.)	SLC26A2, . (Multiple	23370
	PRPS1, . (Art's Syndrome, Gene PRPS1, Mut.)	27250
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene ALOXE3, Mut.)	(- - - - -) . ALOXE3, .	58330
	PAX3, . (Craniofacial-Deafness-Hand Syndrome, CDHS, Gene PAX3, Mut.)	31140
Muscular Dystrophy, Gene LMNA, Mut.)	LMNA, . (Emery-Dreifuss	38910
VHL, . (Autosomal Recessive Erythrocytosis, Gene VHL, Freq. Mut.)	(c - - - - -) .	4680
(Keratitis-Ichthyosis-Deafness Syndrome, KID Syndrome, Gene GJB2, Mut.)	(- - - - -) . GJB2, .	9090
« » . (Familial Partial Lipodystrophy 2, FPLD 2, Gene LMNA, Hot-Point Mut.)	« » LMNA,	12970

TAZ, . (Barth Syndrome, Gene TAZ, Mut)	23370
ERCC6, . (Cerebrooculofacioskeletal Syndrome, COFS Syndrome, Gene ERCC6, Mut.)	85530
VHL, . (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Copy Number Variation Gene VHL, Mut.)	15070
EXT2, . (Multiple Exostoses, Gene EXT2, Mut.)	58330
CAPN3, FKR, ANO5, SGCA	10960
CYP1B1, . (Primary Congenital Glaucoma 3A, PCG 3A, Gene CYP1B1, Mut.)	15930
13 SCN4A, . (Normokalemic Periodic Paralysis, Exon 13 Gene SCN4A, Mut.)	6510
ATP7B, PNPLA3, SERPINA1, . .	8400
GLI3, . (Polydactyly, Gene GLI3, Mut.)	69990
-IgM Mut.) CD40LG, . (Hyper-IgM Syndrome, Gene CD40LG, Mut.)	19480
HPGD, . (Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1, Gene HPGD, Mut.)	27250
CLCN1, . . (Myotonia Congenita, Gene CLCN1, Freq. Mut.)	9350
, C9orf72, . .	4200
HNF1B, . (Renal Cysts And Diabetes Syndrome, Gene HNF1B, Mut.)	35020
SH3TC2, FIG4, FGD4 GDAP1, . . (Charcot-Marie-Tooth Disease Type 1B, Gene GDAP1, Freq. Mut.)	9350
RPS6KA3, . (Coffin-Lowry Syndrome, Gene RPS6KA3, Mut.)	85530
SHH, . (Polydactyly, Gene SHH, Mut.)	9090
, . PNPLA3, . .	2900
TAR. TAR-Syndrome, Gene RBM8A, Mut.) RBM8A, . (Thrombocytopenia-Absent Radius Syndrome,	23370
PTEN, . (Cowden Syndrome 1, Gene PTEN, Mut.)	35020
, 2, CNBP (ZNF9), . .	2800
EBP, . (Chondrodysplasia Punctata, CDP, Conradi-Hunermann Syndrome, Gene EBP, Mut.)	15600
STXBP2, . (Familial Hemophagocytic Lymphohistiocytosis, Gene STXBP2, Mut.)	46680
LPIN1, . (Myoglobinuria Acute Recurrent Autosomal Recessive, Gene LPIN1, Mut.)	85530
ADAMTSL2, . (Geleophysic Dysplasia 1, Gene ADAMTSL2, Mut.)	69990
PANK2, . . (Neurodegeneration With Brain Iron Accumulation 1, Gene PANK2, Freq. Mut.)	6510
GJB4, . (Erythrokeratodermia, Gene GJB4, Mut.)	9090
SLC26A2, . (Atelosteogenesis II, De la Chapelle Dysplasia, Gene SLC26A2, Mut.)	23370
RPS19, . (Diamond-Blackfan Anemia 1, DBA1, Gene RPS19, Mut.)	19480
NPHS2, . (Nephrotic Syndrome Type 1, NPHS1, Gene NPHS2, Mut.)	31140
IX B, . (Hemophilia B, Gene Factor IX, Mut.)	27250
TRPS1, . (Trichorhinophalangeal Syndrome, TRPS, Gene TRPS1, Mut.)	38910
IGHMBP2, . (Spinal Muscular Atrophy (SMA) with Diaphragmatic Paralysis, Gene IGHMBP2, Mut.)	58330
FGFR3, . . (Hypochondroplasia, Gene FGFR3, Freq. Mut.)	10960
NS3, NS5A NS5B (1 , 1b)	11670
13 24 SCN4A, . (Hyperkalemic Periodic Paralysis Type 2, Exons 13, 24 Gene SCN4A, Mut.)	14270

DFNB1	GJB2	6200
MET		11210
(Hereditary Breast and/or Ovarian Cancer, HBOC (Genes BRCA1, BRCA2))	BRCA1, BRCA2	4350
POLE		7570
1 /19q		10150
		9100
Neoplasia Type 2B (Gene RET))	2B (RET) (Multiple Endocrine	4680
BRCA-	BRCA1, BRCA2) (3900
(Hereditary Breast Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2) (without Description))		
Medullary Thyroid Cancer (Exons 10, 11, 13, 14, 15 Gene RET))	10, 11, 13, 14, 15 RET) (Familial	19460
Endocrine Neoplasia Type 2A (Exons 10, 11 Gene RET))	2A (10, 11 RET) (Multiple	9090
IDH2		10620
		21090
14 JAK2 (Quantification of wild-type and mutant allelic ratio of gene JAK2 617V/617F)	617V/617F	8000
BRCA-	BRCA1, BRCA2) (Hereditary Breast	4350
Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2))		
MGMT		10620
PIK3CA		10620
228 250 TERT		7570
(Hereditary Breast and/or Ovarian Cancer, HBOC (Genes BRCA1, BRCA2) (without Description))	BRCA1, BRCA2) (3900
IDH1		10620
A09.05.039 Dehydrogenase, LDH)	(, L- , +) (Lactate	150
G6PD		2980
A09.05.042) (Alanine Aminotransferase, ALT, Serum Glutamic Pyruvic Transaminase, SGPT)		150
A09.05.045 (?- ,) (lpha- milase, ?-Amylase)		210
A09.05.180 - (P-) (Pancreatic ?-Amylase)		250
(S- , II, S-) (Cholinesterase, Pseudocholinesterase, PCHE)		230
A09.05.046 () (Alkaline Phosphatase, ALP)		150
A09.05.173 () (Lipase)		290
() (Acid Phosphatase, ACP)		200
- (,) (Gamma-Glutamyl Transferase, GGT)		150
A09.05.043 Phosphokinase, CPK)	(, ,) (Creatine Kinase, CK, Creatine	240
A09.05.041 ,) (Aspartateaminotransferase, AST, Serum Glutamicoxaloacetic Transaminase, SGOT)	(, , -	150
- (- , - , -) (Creatine Kinase-MB, CK-MB, Creatine Phosphokinase-MB, CPK-MB.)		310
HLA-		
HLA II (DRB1, DQA1, DQB1) (System Human Leukocyte Antigen (HLA) Class II, Typing (Genes DRB1, DQA1, DQB1))		5310
(Genotype of RH factor Definition (without Description))		8880

the fetus in the mother's blood)	Y-	(Y-chromosome of	4100
(Rh factor Definition)			6200
(Plasminogen)			600
VIII () (Antihemophilic Globulin A, FVIII)	1030
A09.05.051.001 D-		(D-Dimer)	1030
A09.05.050		(Fibrinogen, FG)	210
A12.05.039		() (
() (Activated Partial Thromboplastin Time, APTT)	150
IX,		% (« ») Factor IX, Activity,%
(Christmas Factor, anti-hemophilic globulin "B")			440
A12.05.027		(), (
Ratio, INR)) (Prothrombin, rothrombin Time, PT, International Normalized	230
A12.05.028		() (Thrombin Time, TT)	230
A09.05.029.001		() (Lupus Anticoagulant, LA)	730
C, %		(Protein C, % Activity)	1790
-		/ (), /), Anti-Xa activity, IU/ml (Heparin concentration, IU/ml)
		, % (Willebrand Factor, Antigen, %)	2030
A09.05.047		III, % (III, Antithrombin III, % Activity)	330
S		(Protein S, Free)	2220
light chains (FLC) kappa and lambda)		(Urine immunoglobulin free	1340
-		() (M-Gradient, Screening. Serum Protein Electrophoresis (SPEP), Immunofixation with Polyvalent Antiserum, Quantification of M-Protein (without Typing))
		(Bence-Jones Protein, Urine, Electrophoresis, Immunofixation, Kappa/Lambda Typing, Quantification)	3000
A09.05.014		(Serum Protein Electrophoresis, SPE, SPE)*	250
-		(IgG, IgA, IgM,), (M-Gradient, Typing. Serum Protein Electrophoresis (SPEP), Immunofixation with Antisera (IgG, IgA, IgM, Kappa, Lambda), Quantification of M-Protein)
Concentration of Immunoglobulin Free Light Chains)		(Cerebrospinal Fluid	1580
/			1960
-		(Bence-Jones Protein, Urine, Immunofixation, Quantification)	1880
A09.05.011		(Albumin)	210
A09.05.010		(Protein Total)	150
A09.05.214		(Homocysteine)	1290
		(Urine Protein Electrophoresis)	1500
ImmunoCAP			
		(f216) IgE, ImmunoCAP	630
		(f33) IgE, ImmunoCAP	630
		, nArtv1 (w231) IgE, ImmunoCAP	1830
		(f9) IgE, ImmunoCAP	630
		(f260), IgE, ImmunoCAP (Broccoli, Brassica oleracea (f260), IgE, ImmunoCAP)	720
		(f26) IgE, ImmunoCAP	630
		() (i6) IgE, ImmunoCAP
			630

(f343), IgE, ImmunoCAP (Raspberry, Rubus idaeus, IgE, ImmunoCAP)	720
(f35) IgE, ImmunoCAP	630
, nGal d3 (f323) IgE, ImmunoCAP	830
(Hollister-Stier) (hx2) IgE, ImmunoCAP	1250
Candida albicans (m5) IgE, ImmunoCAP	630
(i1) IgE, ImmunoCAP	630
(i3) IgE, ImmunoCAP	630
(c8) IgE, ImmunoCAP	630
(f95) IgE, ImmunoCAP	630
(f6) IgE, ImmunoCAP	720
(Saccharomyces cerevisiae) (f45) IgE, ImmunoCAP	630
, nGal d1 (f233) IgE, ImmunoCAP	830
, rAra h 2 (f423) IgE, ImmunoCAP	1830
, (e81) IgE, ImmunoCAP	630
/ D. pter nyssinus (d1) IgE, ImmunoCAP	630
, rBet v1/PR-10 (t215) IgE, ImmunoCAP	1830
(f23) IgE, ImmunoCAP	630
, nGal d2 (f232) IgE, ImmunoCAP	830
- , (nBos d5) (f77) IgE, ImmunoCAP	830
- (nBos d4) (f76) IgE, ImmunoCAP	830
(f92) IgE, ImmunoCAP	630
(f91) IgE, ImmunoCAP	630
, (e6) IgE, ImmunoCAP	630
, ImmunoCAP	2750
, rGly m 4/PR-10 (f353) IgE, ImmunoCAP	1830
, (e213) IgE, ImmunoCAP	630
(f75) IgE, ImmunoCAP	630
, (e1) IgE, ImmunoCAP	630
, rAra h 1 (f422) IgE, ImmunoCAP	1830
(Hollister -Stier) (h2) IgE, ImmunoCAP	630
c, rAra h 9 LTP (f427) IgE, ImmunoCAP	1830
, rCan f 1 (e101) IgE, ImmunoCAP	1830
(f83) IgE, ImmunoCAP	630
(w5) IgE, ImmunoCAP	630
Malassezia spp. (m227) IgE, ImmunoCAP	630
, rCan f 2 (e102) IgE, ImmunoCAP	1830
/ (k80) IgE, ImmunoCAP	630
(f31) IgE, ImmunoCAP	630
(f14) IgE, ImmunoCAP	630
(Greer Labs.) (h1) IgE, ImmunoCAP	630
c (k82) IgE, ImmunoCAP	630
Cladosporium herbarum (m2) IgE, ImmunoCAP	630
(w8) IgE, ImmunoCAP	720
(mx2) IgE, ImmunoCAP	1250
(f24) IgE, ImmunoCAP	630
, rPen a1(f351) IgE, ImmunoCAP	1830

(f209) IgE, ImmunoCAP	630
(i71) IgE, ImmunoCAP	630
(f2) IgE, ImmunoCAP	630
() (f55) IgE, ImmunoCAP	630
(f210) IgE, ImmunoCAP	630
(f13) IgE, ImmunoCAP	630
, nArtv3 (w233) IgE, ImmunoCAP	1830
-5, rTri a 19 (f416) IgE, ImmunoCAP	1830
(fx15) IgE, ImmunoCAP	1250
, (e5) IgE, ImmunoCAP	630
(fx73) IgE, ImmunoCAP	1250
(fx5) IgE, ImmunoCAP	1250
(w204) IgE, ImmunoCAP	720
(f49) IgE, ImmunoCAP	630
Penicillium notatum (P.chrysogenum) (m1) IgE, ImmunoCAP	630
(f25) IgE, ImmunoCAP	630
, rCyp c 1 (f355) IgE, ImmunoCAP	1830
(i75) IgE, ImmunoCAP	630
(gx1) IgE, ImmunoCAP	1250
, rBet v2, rBet v4 (t221) IgE, ImmunoCAP	1830
(f11), IgE, ImmunoCAP	630
(m80) IgE, ImmunoCAP	630
Phadiatop ImmunoCAP, IgE	1570
, rPhl p1, rPhl p5 (g213) IgE, ImmunoCAP	1830
(f302) IgE, ImmunoCAP	720
, (nBos d8) (f78) IgE, ImmunoCAP	830
(mx1) IgE, ImmunoCAP	1250
V (c2) IgE, ImmunoCAP	630
(f227) IgE, ImmunoCAP	720
(tx9) IgE, ImmunoCAP	1250
(f12), IgE, ImmunoCAP (Pea, Pisum sativum, IgE, ImmunoCAP)	720
(f20) IgE, ImmunoCAP	720
() (f212), IgE, ImmunoCAP (Mushrooms, Agaricus hortensis, IgE, ImmunoCAP)	720
/ D. farina (d2) IgE, ImmunoCAP	630
(f88) IgE, ImmunoCAP	630
(f94), IgE, ImmunoCAP (Pear, Pyrus communis, IgE, ImmunoCAP)	720
(f17) IgE, ImmunoCAP	630
(f4) IgE, ImmunoCAP	630
(f208) IgE, ImmunoCAP	630
, nBos d6 BSA (e204) IgE, ImmunoCAP	1830
(f262), IgE, ImmunoCAP (Eggplant, Solanum melongena, IgE, ImmunoCAP)	720
(f221), IgE, ImmunoCAP (Coffee, Coffea spp., IgE, ImmunoCAP)	720
(f222) IgE, ImmunoCAP	720
(wx1) IgE, ImmunoCAP	1250
(f322) IgE, ImmunoCAP	720
(f93) IgE, ImmunoCAP	630

, rPhl p7, rPhl p12 (g214) IgE, ImmunoCAP	1830
, rFel d1 (e94) IgE, ImmunoCAP	1830
(f27) IgE, ImmunoCAP	630
(f84) IgE, ImmunoCAP	630
, nGal d4 (k208) IgE, ImmunoCAP	830
, nAmb a1 (w230) IgE, ImmunoCAP	1830
(w6) IgE, ImmunoCAP	630
(f48), IgE, ImmunoCAP (Onion, Allium cepa, IgE, ImmunoCAP)	720
G (c1) IgE, ImmunoCAP	630
(g6) IgE, ImmunoCAP	630
(t3) IgE, ImmunoCAP	630
, rFel d2 (e220) IgE, ImmunoCAP	1830
B (m81) IgE, ImmunoCAP	630
(f237), IgE, ImmunoCAP (Apricot, Prunus armeniaca, IgE, ImmunoCAP)	720
(f242), IgE, ImmunoCAP (Cherry, Prunus avium, IgE, ImmunoCAP)	720
Ig E ImmunoCAP	690
TSST (m226) IgE, ImmunoCAP	630
Alternaria alternata (m6) IgE, ImmunoCAP	630
Aspergillus fumigatus (m3) IgE, ImmunoCAP	630
(f47) IgE, ImmunoCAP	720
Phadiatop Infant ImmunoCAP, IgE	1990
, rAra h 3 (f424) IgE, ImmunoCAP	1830
(f1) IgE, ImmunoCAP	630
c (f7) IgE, ImmunoCAP	630
c, rAra h 8/PR-10 (f352) IgE, ImmunoCAP	1830
(f85) IgE, ImmunoCAP	630
, (f44) IgE, ImmunoCAP	630
(f225) IgE, ImmunoCAP	630
(i2) IgE, ImmunoCAP	630
(f300) IgE, ImmunoCAP	720
(f3) IgE, ImmunoCAP	630
, (e85) IgE, ImmunoCAP	630
, nCan f3 (e221) IgE, ImmunoCAP	1830
(w206) IgE, ImmunoCAP	720
Alternaria alternata, rAlt a 1 (m229) IgE, ImmunoCAP	1830
- HLA-B27 (Molecular Genetic Testing HLA-B27)	1550
() (Anti- ydic Citrullinated Peptide, anti-CCP)	1320
IgG () (Anti- eratin ntibodies, AKA, Anti-Filaggrin ntibodies, AFA, IgG)	2040
, IgA (IgA; Rheumatoid Factor, RF, IgA)	1120
() (Synovial Fluid Smear, Crystals)	1550
IgG (-M) (Anti-Mutated Citrullinated Vimentin Antibodies, Anti-MCV, Anti-Modified Citrullinated Vimentin Antibodies, Anti-Sa Antibodies, IgG)	1380

		(CMV DNA, Scrape of Nasal Epithelial Cells)*	250
		(CMV DNA, Scrape of Faucial Epithelial Cells)*	250
		(CMV DNA, Blood)*	380
		(CMV DNA, Exudate)*	250
		(CMV DNA, Serum)*	380
A	IgM	(Anti-CMV IgM)	490
		(CMV DNA, Prostatic Fluid, Semen)*	250
		(CMV DNA, Scrape of Skin Epithelial Cells)*	250
		(CMV DNA, Urine)*	250
		(CMV DNA, Scrape of Urogenital Epithelial Cells)*	250
		(CMV DNA, Saliva)*	250
		(Cytomegalovirus, DNA)	370
		Anti-CMV IgG	1040
A	IgG	(Anti-CMV IgG)	360
		(CMV DNA, Scrape of Conjunctiva Epithelial Cells)*	250
		(CMV DNA, Cerebrospinal Fluid)*	250
		(Copper, random urine; Cu)	1180
	(Cd)	(Cadmium (Cd), Urine)	1180
	(Co)	(Cobalt (Co), Urine)	1180
	(Tl)	(Thallium (Tl), Urine)	1180
	(I)	(Iodine (I), Urine)	1180
	(Mn)	(Manganese (Mn), Urine)	1180
	(Fe)	(Iron (Fe), Urine)	1180
	(Hg)	(Mercury (Hg), Urine)	1180
	(Al)	(Aluminum (Al), Urine)	1180
	()	()	680
	(Zn)	(Zinc (Zn), Urine)	1180
	(Cu)	(Copper (Cu), 24-Hours Urine)	1180
	(Ni)	(Nickel (Ni), Urine)	1180
	(Se)	(Selenium (Se), Urine)	1180
	()	()	680
	(Pb)	(Lead (Pb), Urine)	1180
	(As)	(Arsenic (As), Urine)	1180
	IgG	(Anti-Tetanus toxoid IgG)	900
	(Ni)	(Nickel (Ni), Serum)	250
	(Hg)	(Mercury (Hg), Blood)	1180
	()	()	680
	(As)	(Arsenic (As), Serum)	250
	(Cd)	(Cadmium (Cd), Serum)	250
	(Co)	(Cobalt (Co), Serum)	250

(Ni)	(Nickel (Ni), lood)	1180
(Zn)	(Zinc (Zn), lood)	1180
	(Iodine, serum)	250
(Au)	(Gold (Au), Serum)	250
(Cu)	(Copper (Cu), Serum)	250
	()	680
(Cu)	(Copper (Cu), lood)	1180
(Pb)	(Lead (Pb), lood)	1180
(Mn)	(Manganese (Mn), lood)	1180
(Zn)	(Zinc (Zn), Serum)	250
(Li)	(Lithium (Li), serum)	250
(Cd)	(Cadmium (Cd), lood)	1180
(Se)	(Selenium (Se), Serum)	250
(Se)	(Selenium (Se), lood)	1180
(Mn)	(Manganese (Mn), Serum)	250
(Co)	(Cobalt (Co), lood)	1180
	(3 , Reverse Triiodthyronine).	5970
(Tl)	(Thallium (Tl), Serum)	250
	()	680
(Mo)	(Molybdenum (Mo), Serum)	250

ATM (FISH,) (Analysis of ATM gene rearrangements (FISH, quantitative))		9850
MPL, (Analysis of MPL gene mutations, PCR, qualitative)		4390
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27)) on paraffin slides (FISH Histology, quantitative))		13570
MLL/AF4 -t(4;11) (,) (Analysis of chimeric gene MLL/AF4 -t(4;11) (PCR, qualitative))		2260
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27) (FISH, quantitative))		9850
13 - (del(13), -13) (FISH,) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH, quantitative))		9850
53 (FISH,) (Analysis of 53 gene deletion (FISH, quantitative))		9850
t(2;5)(p23;q35) (FISH,) (Analysis of translocation t(2;5)(p23;q35) on paraffin slides (FISH Histology, quantitative))		13570
(FISH,) (Analysis of all specific aberrations on paraffin slides (FISH Histology, quantitative))		13570
t(11;14)(q13;q32) (FISH,) (Analysis of translocation t(11;14)(q13;q32) on paraffin slides (FISH Histology, quantitative))		13570
t(11;14)(q13;q32) (FISH,) (Analysis of translocation t(11;14)(q13;q32) (FISH, quantitative))		9850
PML/RAR? -t(15;17) (,) (Analysis of chimeric gene PML/RAR? -t(15;17) (PCR, qualitative))		2260
CBF?/MYH1- inv(16),t(16;16) (,) (Analysis of chimeric gene CBF?/MYH1- inv(16),t(16;16) (PCR, qualitative))		2260
12 (+12) (FISH,) (Analysis of chromosome 12 trisomy (FISH, quantitative))		9850
V617F 14 JAK2 (Qualitative assessment of presence of gene JAK2 617F somatic mutation)		1770
t(11;18)(q21;q21) (FISH,) (Analysis of translocation t(11;18)(q21;q21) (FISH, quantitative))		9850
(Karyotype, Hematologic Disorders, Peripheral Blood)		7020
53 (FISH,) (Analysis of 53 gene deletion (FISH, quantitative))		9850
t(14;16) (IGH/MAFB) (FISH,) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH, quantitative))		9850

BCR/ABL - t(9;22), (Analysis of chimeric gene BCR-ABL - t(9;22), assessment of the BCR-ABL gene transcript type, PCR, qualitative)	BCR/ABL -	2260
12p (FISH,) (Analysis of 12p deletion (FISH, quantitative))		9850
BCR-ABL (FISH,) (Analysis of chimeric gene BCR-ABL, FISH, quantitative)		9850
BCL2 (FISH,) (Analysis of BCL2 gene rearrangements on paraffin slides (FISH Histology, quantitative))		13570
PDGFR?(FISH,) (Analysis of gene rearrangements PDGFR? (FISH, quantitative))		9850
FGFR1 (FISH,) (Analysis of gene rearrangements FGFR1 (FISH, quantitative))		9850
E2A/PBX1 - t(1;19) (,) (Analysis of chimeric gene E2A/PBX1 - t(1;19) (PCR, qualitative))		2260
BRAF (V600E) (,)		7790
5 (FISH,) (Analysis of chromosome 5 rearrangements (FISH, quantitative))		9850
t(4;14)(p16;q32) (FISH,) (Analysis of translocation t(4;14)(p16;q32) (FISH, quantitative))		9850
t(14;16) (IGH/MAFB) (FISH,) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH,quantitative))		9850
BCR/ABL - RQ () (Analysis of the BCR/ABL relative expression, RQ-PCR, quantitative)		4390
() (Cytogenetic analysis of bone marrow (karyotype))		7020
FIP1L1/PDGFR?(FISH,) (Analysis of chimeric gene FIP1L1/PDGFR? (FISH, quantitative))		9850
MLL (FISH,) (Analysis of MLL gene rearrangements (FISH, quantitative))		9850
7 (FISH,) (Analysis of chromosome 7 rearrangements (FISH, quantitative))		9850
13 - (del(13), -13) (FISH,) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH,quantitative))		9850
12 JAK2 (,) (Analysis of JAK2 Exon 12 mutations (PCR qualitative))		4390
BCL2 t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH,) (Analysis of BCL2 gene rearrangements t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH, quantitative))		9850
BCR-ABL () (BCR-ABL1 Mutation Analysis using direct Sanger sequencing, qualitative)		8760
1 (FISH,)		12970
3q (FISH,) (Analysis of 3q rearrangements (FISH, quantitative))		9850
RUNX1/RUNX1T1 -t(8;21) (,) (Analysis of chimeric gene RUNX1/RUNX1T1 -t(8;21) (PCR, qualitative))		2260
20q (FISH,) (Analysis of 20q deletion (FISH, quantitative))		9850
MYC (t(8;14)(q24;q32)-t(2;8)(p11;q24), t(8;22)(q24;q11)) (FISH,) (Analysis of MYC gene rearrangements (t(8;14)(q24;q32)-t(2;8)(p11;q24), t(8;22)(q24;q11) (FISH, quantitative))		9850
CALR (,) (Analysis of CALR gene mutations, deletions, insertions, PCR, qualitative)		4390
IGH (FISH,) (Analysis of IGH gene rearrangements (FISH, quantitative))		9850
t(2;5)(p23;q35) (FISH,) (Analysis of translocation t(2;5)(p23;q35) (FISH, quantitative))		9850
:		
		1200
() (Additional research participant (child or mother or father))		5730
(3) (Urgent Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))		38030
(2) (Urgent Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		38030
(2) (Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		16170

(3) (Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))	18080
(Koprogramma, Stool)	340
	3690
	5570
(Fecal Calprotectin)	2380
	3220
-1- (Alpha-1-Antitrypsin, Feces)	1570
	1330
	230
() (PRO Stool, Helminth Eggs)	280
	1800
(), FOB Gold (Quantitative Immunochemical Fecal Occult Blood, Test FOB Gold)	650
1 (1), 1 (Elastase 1, E1)	2520
() (Stool Sugars, Reducing Substances, Fecal)	560
(PRO Stool)	280
(), (nterobiasis, Spatula)	260
(Stool osmotic gap)	1150
-10 (-10) (Interleukin 10, IL-10)	1850
-6 (-6) (Interleukin 6, IL-6)	1850
-? (-?) (Tumor Necrosis Factor Alpha, TNF-?, Cachectin)	1850
-1? (-1?) (Interleukin 1 Beta, IL-1)	1850
-8 (-8) (Interleukin 8, IL-8)	1850
IgE:	
, IgE (Food Allergy Panel, IgE)	3670
, IgE (Celery, IgE, F85)	440
, IgE (Milk, IgE, F2)	440
(f96), IgE, ImmunoCAP (Avocado, Persea americana, IgE, ImmunoCAP)	720
, IgE (Chicken Meat, IgE, F83)	440
(f244) IgE, ImmunoCAP	720
, IgE (Pineapple, IgE, F210)	440
, IgE (Grapefruit, IgE, F209)	440
- , IgE (Beta Lactoglobulin, IgE, F77)	440
, IgE (Egg Yolk, IgE, F75)	440
(g4) IgE, ImmunoCAP	720
, IgE (Shrimp, IgE, F24)	440
, IgE (Rice, IgE, F9)	440
, IgE (Strawberry, IgE, F44)	440
, IgE (Apple, IgE, F49)	440
, IgE (Pork, IgE, F26)	440
, IgE (Lamb, IgE, F88)	440
, IgE (Tomato, IgE, F25)	440
, IgE (Baker's Yeast, IgE, F45)	440

, IgE (Potato, IgE, F35)	440
, IgE (Lemon, IgE, F208)	440
, IgE (Peach, IgE, F95)	440
3: , IgE (FP73 (F26, F27, F83, F88), Food Panel: Pork, Beef, Chicken Meat, Lamb, IgE)*	950
" 2"	1745
, IgE (Casein, IgE, F78)	440
, IgE (Kiwi Fruit, IgE, F84)	440
, IgE (Cabbage, IgE, F216)	440
, IgE (Codfish, IgE, F3)	440
, IgE (Wheat, IgE, F4)	440
1: , IgE (FP15 (F33, F49, F92, F95), Food Panel: Orange, Banana, Apple, Peach, IgE)*	950
, IgE (Carrot, IgE, F31)	440
, IgE (Common Millet, IgE, F55)	440
, IgE (Banana, IgE, F92)	440
, IgE (Soybean, IgE, F14)	440
, IgE (Chocolate, IgE, F105)	440
, IgE (Egg White, IgE, F1)	440
2: , IgE (FP50 (F84, F91, F92, F210), Food Panel: Kiwi Fruit, Mango, Banana, Pineapple, IgE)*	950
, IgE (Pumpkin, IgE, F225)	440
, IgE (Hazelnut, IgE, F17)	440
, IgE (Orange, IgE, F33)	440
, (e3) IgE, ImmunoCAP (f329), IgE, ImmunoCAP (Watermelon, Citrullus lanatus, IgE, ImmunoCAP)	720
(f5) IgE, ImmunoCAP	720
, IgE (Beef, IgE, F27)	440
, IgE (Oat, IgE, F7)	440
" 1"	1745
, IgE (Buckwheat, IgE, F11)	440
, IgE (Brewer's Yeast, IgE, F403)	520
, IgE (Crab, IgE, F23)	440
, IgE (Peanut, IgE, F13)	440
, IgE (Mango, IgE, F91)	440
(Ca) (Calcium (Ca), air)	1180
(Co) (Cobalt (Co), air)	1180
(Zr) (Zirconium (Zr), air)	1180
(Mg) (Magnesium (Mg), air)	1180
(Be) (Beryllium (Be), air)	1180
(Pb) (Lead (Pb), air)	1180
(Mo) (Molybdenum (Mo), air)	1180
(Al) (Aluminum (Al), air)	1180
(Hg) (Mercury (Hg), air)	1180
(Mn) (Manganese (Mn), air)	1180
(Se) (Selenium (Se), air)	1180
(V) (Vanadium (V), air)	1180

(Si)	(Silica (Si), air)	1180
(Rb)	(Rubidium (Rb), air)	1180
(Bi)	(Bismuth (Bi), air)	1180
(P)	(Phosphorus (P), air)	1180
()	()	680
(Cu)	(Copper (Cu), air)	1180
(Sb)	(Antimony (Sb), air)	1180
(I)	(Iodine (I), air)	1180
(Ba)	(Barium (Ba), air)	1180
(B)	(Boron (B), air)	1180
(La)	(Lanthanum (La), air)	1180
(Fe)	(Iron (Fe), air)	1180
(Ag)	(Silver (Ag), air)	1180
(Cr)	(Chromium (Cr), air)	1180
(Sr)	(Strontium (Sr), air)	1180
(W)	(Tungsten, Wolframium (W), air)	1180
(Na)	(Sodium (Na), air)	1180
(Pt)	(Platinum (Pt), air)	1180
(Ge)	(Germanium (Ge), air)	1180
(As)	(Arsenic (As), air)	1180
(Cd)	(Cadmium (Cd), air)	1180
(K)	(Potassium (K), air)	1180
(Ni)	(Nickel (Ni), air)	1180
(Zn)	(Zinc (Zn), air)	1180
(Sn)	(Tin (Sn), air)	1180
(Li)	(Lithium (Li), air)	1180
(Au)	(Gold (Au), air)	1180
(Tl)	(Thallium (Tl), air)	1180
(Ga)	(Gallium (Ga), air)	1180

IgG () (Extractable Nuclear Antigen, ENA, Anti-Ribonucleoprotein Antibodies, Anti-RNP)		1120
(Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Sc100, PM-Sc175, Ku, PDGFR, Ro-52), (Scleroderma (Systemic Sclerosis) Antibody Panel: Anti-Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Sc100, PM-Sc175, Ku, PDGFR, Ro-52, Immunoblotting)		4010
(), (Anti-Nuclear Antibodies, ANA, Screening)		470
(, HEp-2 (, HEp-2) (Antinuclear Antibodies, ANA, Hep-2 Substrate, ANA-Hep2, Fluorescent Anti-Nuclear Antibodies detection, FANA, iters)		1150
(Sm, RNP/Sm, SS-A (60), SS-A (52), SS-B, Scl-70, PM-Scl, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Jo-1), (ANA: Anti-Sm, RNP/Sm, SS-A (60 kD), SS-A (52 kD), SS-B, Scl-70, PM-Scl, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Anti-Jo-1, Immunoblotting)		3190
IgG (a), (Anti-Nuclear Antibodies, ANA, IgG, Screening)		1120
(,)		990
IgG (- IgG, -) (Double-Stranded (Native) DNA IgG Antibodies, Anti-dsDNA IgG)		570
(, IgG)		1570

B03.016.014	(Nechiporenko's Urine Test)	230
	() (Sulkowitch Urine Calcium Test)	130
B03.016.006	() (Complete Urinalysis, Microscopic Examination)	230
(, Hepatitis C Virus, HCV)		
(Hepatitis C Virus (HCV) RNA, Quantitative PCR, Genotyping (Types 1, 2, 3))	(1, 2, 3)	3680
-28 (-28), ()	() (Interleukin 28 Beta IL28B, Genotyping (Study of Genetic Markers Determining Effectiveness of Treatment of Chronic Hepatitis C in Interferon and Ribavirin))	720
Quantitative)*	(CITO), (HCV RNA, Plasma,	20940
(), (Hepatitis C Virus (HCV) RNA, Ultrasensitive PCR)		3050
IgM IgG (Anti-HCV Total (IgG + IgM))*		360
IgG (Anti-HCV IgG, Immunoblot)	C,	5110
Qualitative)*	(HCV RNA, Serum,	630
RNA, Serum, Quantitative, PCR)*	(HCV	3140
1a 1b), 2, 3) (Hepatitis C Virus (HCV) RNA, Plasma, Genotyping, Subtypes (Types 1 (Subtypes 1a, 1b), 2, 3))*	(1 (840
Quantitative)*	(HCV RNA, Plasma,	10470
(, Staphylococcus aureus)		
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		980
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)		1950
(Staphylococcus aureus) (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification)		650
(Staphylococcus aureus, (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		980
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)		1950
Bacteria Identification) (Staphylococcus aureus) (Staphylococcus aureus Culture.		650
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(- 1 2 , Herpes simplex virus, HSV-1, HSV-2)		
1 2 , (HSV-1, 2 DNA, Urine)*		250
1 2 , (HSV-1, 2 DNA, Serum, yping)*		600
1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells, yping)*		420
1 2 , (HSV-1, 2 DNA, Urine, yping)*		420
IgG 1 2 (Anti-HSV-1, 2 IgG)		440

1 2 , , (HSV-1, 2 DNA, Blood, yping)*		600
1 2 , , (HSV-1, 2 DNA, Cerebrospinal Fluid, yping)*		420
1 2 , , (HSV-1, 2 DNA, Exudate)*		250
1 2 , , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells, yping)*		420
Ig 1 2 (Anti-HSV-1, 2 Ig)		460
1 2 , , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells, yping)*		420
1 2 , , (HSV-1, 2 DNA, Saliva, yping)*		420
1 2 , , (HSV-1, 2 DNA, Exudate, yping)*		420
1 2 , , (HSV-1, 2 DNA, Blood)*		380
1 2 , , (HSV-1, 2 DNA, Saliva)*		250
1 2 , , (HSV-1, 2 DNA, Scrape of Skin Epithelial Cells)*		250
1 2 , , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells, yping)*		420
1 2 , , (HSV-1, 2 DNA, Cerebrospinal Fluid)*		250
1 2 , , (HSV-1, 2 DNA, Prostatic Fluid, Semen)*		250
1 2 , , (HSV-1, 2 DNA, Prostatic Fluid, Semen, yping)*		420
IgG 2 (Anti-HSV-2 IgG)		550
1 2 , , (HSV-1, 2 DNA, Serum)*		380
1 2 , , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells)*		250
Anti-HSV IgG		700
1 2 , , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells)*		250
1 2 , , (HSV-1, 2 DNA, Scrape of Skin Epithelial Cells, yping)*		420
IgG 1 (Anti-HSV-1 IgG)		680
1 2 , , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells)*		250
COVID-19		
SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)		690
SARS-CoV-2-IgG- (N-, S-proteins) antibodies, IgG, qualitative	(SARS-CoV-2 (N-, S-), (Post-vaccination (EpiVacCorona Vector) SARS-CoV-2	2260
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1990
spike (S) protein (RBD), IgG, quantitative.	(S) (RBD) SARS-CoV-2, IgG (Anti-SARS-CoV-2,	1290
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1290
SARS CoV-2 (S- , RBD), IgG,		1290
(S) SARS-CoV-2, IgG, (anti-SARS-CoV-2 S (spike) protein antibody, IgG, qualitative. Assessment of immunity before and after vaccination)		890
SARS-CoV-2 (nucleocapsid protein), IgG, Abbott	(SARS-CoV-2 (), IgG, (Anti-SARS-CoV-2	690
SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)		690
A		
IgM Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM)		500
(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Mycoplasma hominis), (Mycoplasma hominis, DNA, Scrape of Urogenital Epithelial Cells)*		250

	(Mycoplasma pneumoniae), pneumoniae, DNA, Plasma)*	(Mycoplasma pneumoniae)	390
	Ig	Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgA)	610
	(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*		210
A	IgG	Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgG)	500
	Ig	Mycoplasma hominis (Anti-Mycoplasma hominis Ig)	420
	(Mycoplasma pneumoniae), pneumoniae, DNA, Sputum)*	(Mycoplasma pneumoniae)	590
	(Mycoplasma hominis), (Mycoplasma hominis, DNA, Prostatic Fluid, Semen)*		250
	IgG	Mycoplasma hominis (Anti-Mycoplasma hominis IgG)	420
	(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Prostatic Fluid, Semen)*		250
	(Mycoplasma pneumoniae), DNA, Saliva)*	(Mycoplasma pneumoniae)	210
	(Mycoplasma hominis), Urine)*	(Mycoplasma hominis, DNA)	250
	IgA	Mycoplasma hominis (Anti-Mycoplasma hominis IgA)	610
	(Mycoplasma genitalium), Urine)*	(Mycoplasma genitalium, DNA)	250
A09.05.127	(Mg)	(Magnesium (Mg), Serum)	230
A09.05.032	(Ca)	(Calcium Total)	190
	/	(Potassium, Na+ /Sodium, Cl-/Chloride, Serum)	250
	(Ca ²⁺ , c)	(Ionized Calcium, Free Calcium)	360
A09.05.033	(P)	(Phosphorus (P))	190
	(UIBC)	(Unsaturated Iron Binding Capacity, UIBC)	190
A09.05.007	(Fe)	(Iron (Fe), Serum)	190
	Helicobacter pylori (Associated Gastritis)*	(Helicobacter pylori)	3640
	PDGFRa		13700
	1	(PDGFRa):	1540
	PD-L1 SP263 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP263 (Ventana) antibodies).	c	16500
	KIT		11600
	Finished Histological Preparations (1 Glass + 1 Block)	(KIT + 1) (Consultation of)	1300
	BRCA1, BRCA2		7400
	(PAS-)		290
	ROS1		8000
	18,19,20, 21	EGFR	9900
	2,3,4	NRAS	7000
	15	BRAF	4800
	2,3,4	KRAS	7000
	PD-L1 SP142 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP142 (Ventana) antibodies).	c	16500
	(MSI)		6200
	HER2 ()		11600
	S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)*	()	18080

() (Pathology of skin biopsies)*	2030
Histochemical Study)* Helicobacter pylori () (Helicobacter pylori, Mucus, ALK	1920
	8000
(; , ; ; -)*	2200
PD-L1 PD-L1 22 3 (Dako). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone 22C3 (Dako) antibodies).	24000
PDL1	7400
() S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)	18080
SCC () (Squamous Cell Carcinoma Antigen, SCCA, SCCAg)	2260
-19-9 (19-9) (Carbohydrate Antigen -19-9, Cancer Antigen-GI)	620
(Chromogranin A, CgA)	4770
() (Carcinoembryonic Antigen, CEA)	570
CA-242 (242, CA-242) (Carbohydrate Antigen -242, Tumor Marker CA-242)	840
ROMA1	70
() (Neuron-Specific Enolase, NSE)	1220
A09.05.130 () (Prostate-Specific Antigen Total, PSA Total)*	440
UBC (8 18) (Urine Bladder Cancer Antigen, Urine Bladder Cancer, UBC)	1860
(, , -2proPSA, phi)	2900
HE4 (4) (Human Epididymis Protein 4, HE4)	1020
-2- (?-2-) (eta-2-Microglobulin, BMG, Serum)	870
A09.05.130 () (Prostate-Specific Antigen Total, PSA Total)	440
ROMA2	70
() (?-Fetoprotein, AFP)	350
-15-3 (15-3) (Carbohydrate Antigen -15-3, Cancer Antigen -15-3)	620
-125 (125) (Carbohydrate Antigen -125, Cancer Antigen -125)	580
A09.05.130.001 ()*	440
CA-72-4 (72-4) (Carbohydrate Antigen -72-4, Cancer Antigen CA-72-4)	870
(Cyfra 21-1, 19) (Cytokeratin 19 Fragments, C-terminus of Cytokeratin 19, CK19 Soluble Fragments, Cyfra 21-1)	860
-2- (?-2-) (Beta-2-Microglobulin, Urine)	870
S100 (S100 protein)	2490
()	
(Trichomonas vaginalis, DNA, Urine)*	250
Prostatic Fluid, Semen)* (Trichomonas vaginalis, DNA,	250
(Trichomonas vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*	250
IgG Trichomonas vaginalis (nti-Trichomonas vaginalis IgG)	610
(Procedural services)	
(Blood serum derivation without further examinations)**	320
	350
(Blood sampling without further examinations)**	190

	(Buccal epithelium sampling, 2 persons)	180
	(Cytological material sampling, PCR diagnosis material sampling, microbiology test material sampling)	350
	(Saliva sampling for PCR)	50
A11.12.009		200
	(Biomaterial sampling for the enterobiasis test)	70
	(Buccal epithelium sampling, 3 persons)	270
	() (capillary blood sampling)	190
	(Buccal epithelium sampling)	90

C

	6 (1 ,1b,2,3 ,4,5 ,6)	2380
--	-----------------------	------

	(Ureaplasma parvum)	360
(Ureaplasma parvum, Effectiveness Monitoring of Treatments)		
(INBIOFLOR ? Mycoplasma, Urogenital Screening)		480
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))		2780
(Bacterial Vaginosis, BV)		1540
MICROBIOCENOSIS (PCR Panel Femoflor 8)	8. (UROGENITAL TRACT	1480
(4 +): Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, (Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)		930
(Mobiluncus curtisii, DNA, Scrape of Urogenital Epithelial Cells)		210
(Mycoplasma hominis, Effectiveness Monitoring of Treatments)	(Mycoplasma hominis)	360
		1700
ur alyticum) (Ureaplasma ur alyticum, Effectiveness Monitoring of Treatments)	(Ureaplasma	360
(7 +), (Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*		1350
MICROBIOCENOSIS (PCR Panel Femoflor 16))	16. (UROGENITAL TRACT	2100
		2000
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	. (UROGENITAL TRACT	1850
		1240
		3820

(As)	(Arsenic (As), Nails)	1180
(Pb)	(Lead (Pb), Nails)	1180
(Sb)	(Antimony (Sb), Nails)	1180
(Cr)	(Chromium (Cr), Nails)	1180
(Sn)	(Tin (Sn), Nails)	1180
(Hg)	(Mercury (Hg), Nails)	1180
(Fe)	(Iron (Fe), Nails)	1180
(Cd)	(Cadmium (Cd), Nails)	1180
(Ge)	(Germanium (Ge), Nails)	1180
(Mo)	(Molybdenum (Mo), Nails)	1180
(P)	(Phosphorus (P), Nails)	1180

()		680
(V)	(Vanadium (V), Nails)	1180
(Bi)	(Bismuth (Bi), Nails)	1180
(Ca)	(Calcium (Ca), Nails)	1180
(La)	(Lanthanum (La), Nails)	1180
(Cu)	(Copper (Cu), Nails)	1180
(Al)	(Aluminum (Al), Nails)	1180
(Au)	(Gold (Au), Nails)	1180
(Ga)	(Gallium (Ga), Nails)	1180
(Se)	(Selenium (Se), Nails)	1180
(Li)	(Lithium (Li), Nails)	1180
(Zn)	(Zinc (Zn), Nails)	1180
(B)	(Boron (B), Nails)	1180
(Ba)	(Barium (Ba), Nails)	1180
(I)	(Iodine (I), Nails)	1180
(Be)	(Beryllium (Be), Nails)	1180
(K)	(Potassium (K), Nails)	1180
(Co)	(Cobalt (Co), Nails)	1180
(W)	(Tungsten, Wolframium (W), Nails)	1180
(Tl)	(Thallium (Tl), Nails)	1180
(Si)	(Silica (Si), Nails)	1180
(Ni)	(Nickel (Ni), Nails)	1180
(Mg)	(Magnesium (Mg), Nails)	1180
(Sr)	(Strontium (Sr), Nails)	1180
(Rb)	(Rubidium (Rb), Nails)	1180
(Na)	(Sodium (Na), Nails)	1180
(Mn)	(Manganese (Mn), Nails)	1180
(Ag)	(Silver (Ag), Nails)	1180
(Zr)	(Zirconium (Zr), Nails)	1180
(Pt)	(Platinum (Pt), Nails)	1180

24-h urine)	, 24- (Estrogens and progesterone metabolites,	6100
,	(Melatonin, plasma)	2400
()		1340

39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35,	
(HPV DNA, Scrape of Rectal Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*		350
, o	4 : 6, 11, 16, 18 +	
Types (6, 11, 16, 18) Screening)	(HPV DNA, Scrape of Urogenital Epithelial Cells, 4	550
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + ,	14 : 16,	
(HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))		350
39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35,	
(HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*		350

Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Rectal	350
Epithelial Cells, 2 Types (16, 18)	16 18 + (HPV DNA, Scrape of Urogenital	350
(6, 11, 44)	3 : 6, 11, 44 (HPV DNA, Scrape of Faucial Epithelial Cells, 3 Types	350
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)	() 14 : 16, 18,	900
Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Urogenital	350
39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Faucial Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	14 : 16, 18, 31, 33, 35,	350
52, 53, 56, 58, 59, 66, 68, 73, 82 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 21 Types (6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82))	21 : 6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51,	2450
39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	14 : 16, 18, 31, 33, 35,	350
	(Candida albicans, DNA, Exudate)*	250
	(Candidiasis, Typing)	670
Susceptibility testing)	(Candida, Cryptococcus) (Yeast Culture. Identification and Antimycotic	690
	(Candidiasis, Screening)	360
Semen)*	(Candida albicans, DNA, Prostatic Fluid,	250
	(Candida albicans, DNA, Scrape of Rectal Epithelial Cells)*	250
	(Candida albicans, DNA, Scrape of Faucial Epithelial Cells)*	250
	Candida albicans, IgG (M5) (M5 Candida albicans, IgG)	520
	(Candidiasis, Screening and Typing)	920
A	IgG Candida albicans (Anti-Candida albicans IgG)	710
	(Candida albicans, DNA, Urine)*	250
Scrape of Skin Epithelial Cells)*	(Candida albicans, DNA,	250
albicans, DNA, Scrape of Urogenital Epithelial Cells)*	(Candida	250
	(Candida albicans, DNA, Saliva)*	250
	()	1670
Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	(Upper Respiratory	1980
Bacteriophage Efficiency Testing)*	(Eye Culture. Bacteria Identification, Antibiotic Susceptibility and	1340
Enlarged Testing)*	(Eye Culture. Bacteria Identification, Antibiotic Susceptibility,	2240
Identification and Antibiotic+ Bacteriophage Susceptibility Testing)	(Stool Culture with Bacteria	1460

(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora. Bacteria Identification and Antibiotic Susceptibility Testing)	1380
(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
()	1570
(Ear Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
(Eye Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Punctate Fluid Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	830
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
(Bile Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1040
(Anaerobic Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	1400
(Sputum and Tracheobronchial washings Culture. Bacteria Identification and Antibiotic Susceptibility Testing, Microscopy)*	1080
(Urine Culture. Bacteria Identification, Antibiotic susceptibility and Bacteriophage Efficiency Testing)*	980
A12.20.001	450
(Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	680
(Breast Milk Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Mycoplasma hominis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	770
(Genitourinary Tract Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Ear Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Urine Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Upper Respiratory Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1020
(Ear Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
() (Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*	1500
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Bile Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2150

(Breast Milk Culture. Bacteria Identification)	650
(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Adenovirus, Immunohistographic Assay), (Adenovirus. One Step Rapid)	870
(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Sputum and Tracheobronchial washings Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing, Microscopy)*	2170
(Helicobacter pylori, Immunohistographic Assay), (Helicobacter pylori. One Step Rapid)	870
() (Upper Respiratory Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	830
(Punctate Fluid Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1980
(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora, Bacteria Identification)	1190
6 ()	2180
1 ()	2180
12 (,) (Cobalamin)	630
(-) (Vitamin E, alpha-Tocopherol, Serum)	2180
5 ()	2180
1,25-D3 (1,25-dihydroxivitamin D3)	1900
3 ()	2180
25(OH)D2 25(OH)D3, (- /)	5460
A09.05.080 (Folic Acid)	870
() (Vitamin A, Retinol, Serum)	2180
1 () (Vitamin K1, Phylloquinone, Serum)	2180
7, ()	2180
12 (, Active-B12, Holotranscobalamin)	1250
-	2180
2 ()	2180
()	2180
	2180
LG1 CASPR2 (), IgG, (VGKC-associated proteins LG1 and CASPR2 antibodies, serum)	5600
, IgG, (Neuronal antibodies, IgG, Indirect immunofluorescence (IIF))	3010
(,), o (Acetylcholine Receptor Antibodies, Anti-AChR, Total)	5210
NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1	12370
IgG, () (Anti-Skeletal Muscle Antibodies, AStMA, IgG)	1110
NMDA, IgG, (-NMDAR IgG, N-methyl-D-Aspartate Receptor Antibodies, CSF)	2760
- IgG (- : Mi-2, Ku, PM-Scl 100/75; Jo1 PL-7 PL-12 EJ OJ; SRP, SSA (Ro52)) (Myositis-Specific Panel)	3670
IgG IgM (- : GM1; GM2-GM3-GM4; GD1a, GD1b, GD2-GD3, GT1a, GT1b, GQ1b,), (Anti-GM1 Antibodies, Anti-GQ1b Antibodies, Anti-Gangliosideantibodies, Ganglioside Antibodies Panel, Total)	5210

Crithidia luciliae, IgG, fluorescent test (CLIFT)	(Crithidia luciliae indirect	1150
IgG,	(Anti-myelin antibody, IgG,	1340
IgA, IgG, IgM	4, (2600
NMO) (Aquaporin-4 Receptor Antibodies, anti-AQP4, Neuromyelitis Optica, NMO, IgA, IgG, IgM, Total)		3990
IgG ()	4980
(Oligoclonal IgG, Cerebrospinal Fluid (CSF), Serum)		12500
(Muscle-specific tyrosine kinase (MuSK) antibody)	(-MuSK)	5600
IgG,	NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1	1890
LG11 CASPR2 (), IgG,	5210
(VGKC-associated proteins LGI1 and CASPR2 antibodies, CSF)		3990
GAD (), IgG, (Anti-GAD (glutamic acid decarboxylase),	
IgG, CSF)		
IgG (- : Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri (ANNA2),) (Anti-Neuronal Antibodies, Blot-Line (Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri (ANNA2), Amphiphysin))		
IgG NMDA (N- -D-)		
(N-Methyl-D-Aspartate Receptor Antibodies IgG)		
Complement (CH50)	(CH50) (Functionality Test of	1340
1- (C1-Esterase Inhibitor, 1-INH)		1960
4 (Complement Component C4)		360
3 (Complement Component C3)		360
IgG (Anti-Rubella IgG, Immunoblot)		5110
Ig (Anti-Rubella Ig)		490
Anti-Rubella IgG		970
(Rubella virus, RNA)		590
IgG (Anti-Rubella IgG)		360
B (Hepatitis B Virus, HBV)		
IgM IgG HB-core B, (Anti-HBc IgM, IgG, Antibodies to Hepatitis B Core Antigen; HBcAb, Total, HBV Core Total Antibodies (IgG + IgM))		470
HBs- (HBs- (HBsAg, Hepatitis Surface Antigen, Quantitative)		1320
HB - (Hepatitis Be Antigen, HBeAg)		510
IgM HB-core B (Anti-HBc IgM Antibodies to Hepatitis B Core Antigen; HBV Core Antibodies IgM)		630
B, (HBV DNA, Serum, Quantitative)*		3410
B, (HBV DNA, Serum, Qualitative)*		380
HBs- (Anti-HBs, HBsAb)		570
HB - (Anti-HBe, HBeAb)		470
HBs- (HBs- (HBsAg, Hepatitis Surface Antigen, Qualitative)		240
2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose and C-Protein Concentration (Fasting and 2 Hours after Load), Venous Blood)		1390
A09.05.023		130
(Lactate)		520
(Fructosamine)		810

A09.05.083	HbA1 (HbA1 , Glycated Hemoglobin, GHB)	460
	() Oral Glucose Tolerance Test, Plasma, OGTT, Pregnancy	900
A12.22.005	2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose Concentration (Fasting and 2 Hours after Load), Venous Blood)	610
A09.05.009	() (C-Reactive Protein, CRP)	310
	(- ,) (Antistreptolysin-O, ASO)	340
-1-	(1), (Alpha-1-Antitrypsin, A1AT, AAT, Phenotyping)	2360
	(-) N- (NT-proBNP, N-Terminal Pro-brain Natriuretic Peptide, Pro-B-Type Natriuretic Peptide)	2560
A09.05.076	(Ferritin)	460
	(Carbohydrate-Deficient Transferrin with results on an electrophoregram (CDT))	3020
	25 () (Hepcidin 25, bioactive)	5970
	ST2 (ST2, sST2,) (Soluble ST2 (Heart Failure's biomarker))	2490
A09.05.008	() (Transferrin)	440
	(Myoglobin)	520
-2-	(Alpha-2-Macroglobulin, ?2-Macroglobulin, A2M)	450
Pgp3 (IgG) Chlamydia trachomatis IgG	520
	() (Rheumatoid Factor, RF)	340
	-I (Troponin-I)	570
	()	540
A09.05.077	(Ceruloplasmin)	590
	(Haptoglobin)	580
-1-	(1), (Alpha-1-Antitrypsin, A1AT, AAT, Concentration)	1260
	(Carbohydrate-Deficient Transferrin, CDT)	2810
	(, Soluble Transferrin Receptor, sTfR)	1700
	(Eosinophil Cationic Protein, ECP)	790
	()	
	(Ureaplasma parvum), (Ureaplasma parvum, DNA, Urine)*	250
	(Ureaplasma arvum), (Ureaplasma parvum, DNA, Prostatic Fluid, Semen)*	250
	IgG Ureaplasma urealyticum (nti-Ureaplasma urealyticum IgG)	610
	(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Scrape of Urogenital Epithelial Cells)*	250
	IgA Ureaplasma urealyticum (nti-Ureaplasma urealyticum IgA)	610
	(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Prostatic Fluid, Semen)*	250
	(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Urine)*	250
	(Ureaplasma arvum), (Ureaplasma parvum, DNA, Scrape of Urogenital Epithelial Cells)*	250
	(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Prostatic Fluid, Semen)*	250
	(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Scrape of Urogenital Epithelial Cells)*	250
	(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Urine)*	250
A	IgG (Anti-Respiratory Syncytial Virus (RSV) IgG)	710

A (RSV) IgM	IgM	-	(Anti-Respiratory Syncytial Virus)	710
(Genes F2, F5)	e	(F2, F5) (Risk of Oral Contraceptives, Ocs)	2730
-	e	(F2, F5) (Risk of Oral Contraceptives, Ocs (Genes F2, F5) (without Description))	2450
)	, 6	(AZF) (3560
MTHFR, MTRR, MTR, F2, F5)	(MTHFR, MTRR, MTR, F2, F5)	(Preparation for Surgery (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))	8010
-	(MTHFR, MTRR, MTR, F2, F5)	(Preparation for Surgery (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))	7180
IgG:				
(F24),	-	IgG	(Shrimp, IgG, F24)	520
(F9),	-	IgG	(Rice, IgG, F9)	520
Food Panel: Orange, Banana, Apple, Peach, IgG)*				950
(F84),	-	IgG	(Kiwi Fruit, IgG, F84)	520
(F11),	-	IgG	(Buckwheat, IgG, F11)	520
(F3),	-	IgG	(Codfish, IgG, F3)	520
Food Panel: Pork, Beef, Chicken Meat, Lamb, IgG)*				950
Food Profile, IgG				14400
(F44),	-	IgG	(Strawberry, IgG, F44)	520
(F7),	-	IgG	(Oat, IgG, F7)	520
(F105),	-	IgG	(Chocolate, IgG, F105)	520
(fx21) IgE, ImmunoCAP				1250
(F4),	-	IgG	(Wheat, IgG, F4)	520
-	,	IgG	(Beta Lactoglobulin, IgG, F77)	520
(F2),	-	IgG	(Milk, IgG, F2)	520
(F25),	-	IgG	(Tomato, IgG, F25)	520
(F55),	-	IgG	(Common Millet, IgG, F55)	520
,	IgG	(Pineapple, IgG, F210)	520	
,	IgG	(Lamb, IgG, F88)	520	
(F26),	-	IgG	(Pork, IgG, F26)	520
(F208),	-	IgG	(Lemon, IgG, F208)	520
,	IgG	(Banana, IgG, F92)	520	
(F75),	-	IgG	(Egg Yolk, IgG, F75)	520
(F1),	-	IgG	(Egg White, IgG, F1)	520
(F83),	-	IgG	(Chicken Meat, IgG, F83)	520
(F35),	-	IgG	(Potato, IgG, F35)	520
,	IgG	(Orange, IgG, F33)	520	
(F209),	-	IgG	(Grapefruit, IgG, F209)	520
(F91),	-	IgG	(Mango, IgG, F91)	520
,	IgG	(Peanut, IgG, F13)	520	
Food Panel: Kiwi Fruit, Mango, Banana, Pineapple, IgG)*				1300
(F225),	-	IgG	(Pumpkin, IgG, F225)	520
(F14),	-	IgG	(Soybean, IgG, F14)	520
(F31),	-	IgG	(Carrot, IgG, F31)	520

(F27),	-	IgG (Beef, IgG, F27)	520
(F45),	-	IgG (Baker's Yeast, IgG, F45)	520
(F216),	-	IgG (Cabbage, IgG, F216)	520
(F403),	-	IgG (Brewer's Yeast, IgG, F403)	520
(F17),	-	IgG (Hazelnut, IgG, F17)	520
(F78),	-	IgG (Casein, IgG, F78)	520
(F95),	-	IgG (Peach, IgG, F95)	520
(F49),	-	IgG (Apple, IgG, F49)	520
- 6			
IgG	6	(Anti-HHV-6 IgG)	610
6	,	(HHV-6 DNA, Saliva)*	250
6	,	(HHV-6 DNA, Scrape of Urogenital Epithelial Cells)*	250
6	,	(HHV-6 DNA, Prostatic Fluid, Semen)*	250
6	,	(HHV-6 DNA, Scrape of Nasal Epithelial Cells)*	250
6	,	(HHV-6 DNA, Urine)*	250
6	,	(HHV-6 DNA, Cerebrospinal Fluid)*	250
6	,	(HHV-6 DNA, Exudate)*	250
6	,	(HHV-6 DNA, Blood)*	380
6	,	(HHV-6 DNA, Scrape of Faucial Epithelial Cells)*	250
6	,	(HHV-6 DNA, Serum)*	380
()			
(Chlamydia pneumoniae), DNA, Saliva)*		(Chlamydia pneumoniae, Chlamydia pneumoniae, DNA, Prostatic Fluid, Semen)*	390
IgG	()	Chlamydia trachomatis (Anti-cHSP60 IgG)	530
A	IgA	Chlamydia trachomatis (Anti-Chlamydia trachomatis IgA)	490
(Chlamydia pneumoniae), pneumoniae, DNA, Plasma)*		(Chlamydia pneumoniae, Chlamydia pneumoniae, DNA, Plasma)*	590
A	IgG	Chlamydia pneumoniae (Anti-Chlamydia pneumoniae IgG)	510
IgM		Chlamydia trachomatis (Anti-Chlamydia trachomatis IgM)	510
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Rectal Epithelial Cells)*		(Chlamydia trachomatis, DNA, Scrape of Rectal Epithelial Cells)*	250
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*		(Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*	250
A	IgG	Chlamydia trachomatis (Anti-Chlamydia trachomatis IgG)	490
		(Helicobacter pylori, DNA, Biopsies of Gastric Mucosa and/or Duodenum, PCR)	2120
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Conjunctiva Epithelial Cells)*		(Chlamydia trachomatis, DNA, Scrape of Conjunctiva Epithelial Cells)*	250
A	IgA	Chlamydia pneumoniae (Anti-Chlamydia pneumoniae IgA)	610
(Chlamydia pneumoniae), DNA, Sputum)*		(Chlamydia pneumoniae, Chlamydia pneumoniae, DNA, Sputum)*	790
A	IgM	Chlamydia pneumoniae (Anti-Chlamydia pneumoniae IgM)	510
(Chlamydia trachomatis), Urine)*		(Chlamydia trachomatis, DNA, (Chlamydia trachomatis, DNA, Urine)*	250
(Chlamydia trachomatis), trachomatis, DNA, Cerebrospinal Fluid)*		(Chlamydia trachomatis, DNA, Cerebrospinal Fluid)*	250
(Chlamydia trachomatis), Exudate)*		(Chlamydia trachomatis, DNA, (Chlamydia trachomatis, DNA, Exudate)*	250
(Chlamydia trachomatis), trachomatis, DNA, Synovial Fluid)*		(Chlamydia trachomatis, DNA, Synovial Fluid)*	460

(Chlamydia pneumoniae), (Chlamydoghila pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*	390
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Faucial Epithelial Cells)*	250
Prostatic Fluid, Semen)* (Treponema pallidum, DNA, (Treponema pallidum, DNA, Scrape of Urogenital Epithelial Cells)*	250
(Treponema pallidum, DNA, Urine)*	250
DNA, Cerebrospinal Fluid)* (Treponema pallidum, (Treponema pallidum, DNA, Serum)*	250
(Treponema pallidum, DNA, Secretion)*	370
A IgM IgG Treponema pallidum, (Anti-Treponema pallidum IgM, (Anti-Treponema pallidum IgG, Total)	250
pallidum, DNA, Scrape of Skin Epithelial Cells)* (Treponema pallidum, DNA, Scrape of Faucial Epithelial Cells)*	380
(Anti-Treponema pallidum IgG, Immunoblot)	250
(Treponema pallidum, DNA, Scrape of Conjunctiva Epithelial Cells)*	250
A IgM Treponema pallidum (Anti-Treponema pallidum IgM)	1790
RPR – (Syphilis RPR (Rapid Plasma Reagins), nticardiolipin est)	250
A IgM Treponema pallidum, (Anti-Treponema pallidum IgM, Immunoblot)	810
A09.05.078 (Testosterone)	210
- (-SO4, Dehydroepiandrosterone sulfate, DHEA-S)	1790
17- (17-) (17-Ketosteroids, Urine)	350
() (Sex Hormone-Binding Globulin, SHBG)	1830
(Androstenedione)	360
A09.05.139 17- - (17-Hydroxyprogesterone, 17-OHP)	1000
A09.05.078.001 (Free Testosterone)	490
() (Androstanediol Glucuronide, 3?-Androstanediol Glucuronid, 3?-diol G)	870
() (Dih drotestosterone, DHT)	1050
() (Protein, random urine, with creatinine and protein/creatinine ratio calculation)	1300
(Magnesium, random urine, with creatinine and magnesium/creatinine ratio calculation)	260
-	530
() (Phosphorus, random urine, with creatinine and phosphorus/creatinine ratio calculation)	280
() (Oxalates, random urine, with creatinine and oxalate/creatinine ratio calculation)	290
() (Albumin, random urine, with creatinine and albumin/creatinine ratio calculation, UACR)	1350
(Calcium, random urine, with creatinine and calcium/creatinine ratio calculation)	450
(Urine Creatinine)	200
IgE:	50

	, IgE (Cockroach, IgE, I6)		440
	, IgE (Dog Epithelium, IgE, E2)		440
	, IgE (Sheep Epithelium, IgE, 81)		440
	, IgE (Budgerigar Feathers, IgE, 78)		440
	, IgE (EP70 (E6, E82, E84, E87, E88), Animal Panel: Guinea Pig Epithelium, Rabbit Epithelium, Hamster Epithelium, Rat, Mouse, IgE)*		950
	, IgE (Guinea Pig Epithelium, IgE, 6)		440
	, IgE (Cat Dander-Epithelium, IgE, E1)		440
	, IgE (Chicken Feathers, IgE, 85)		440
-			
	()		
	1 2 1 2 (HIV Ag/Ab Combo)		290
	-1, (HIV RNA, Plasma)*		12940
-			
	(Everolimus)		3300
	(Cyclosporine, Cyclosporine A, Sandimmune)		950
	() (Teriflunomide, Leflunomide metabolite)		3300
	(Levetiracetam, Keppra®)		3400
	() (carbamazepine, Tegretol)		2620
	(Mitotane, o, p?-DDD, plasma)		3300
	() (Phenytoin)		1160
	() (FK506, Advagraf, Prograf, Protopic, Tacrosel)		1430
	(Lamotrigine)		3400
	() (Acidum Valproicum, Depakin, Convulexs)		810
	A09.05.035.002 () (Phenobarbitalum)		2620
()			
	(Neisseria gonorrhoeae, DNA, Prostatic Fluid, Semen)*		250
	(Neisseria gonorrhoeae, DNA, Scrape of Rectal Epithelial Cells)*		250
	(Neisseria gonorrhoeae, DNA, Synovial Fluid)*		460
	(Neisseria gonorrhoeae,), (GC, Neisseria gonorrhoeae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		900
	(Neisseria gonorrhoeae, DNA, Scrape of Conjunctiva Epithelial Cells)*		250
	(Neisseria gonorrhoeae, DNA, Scrape of Faucial Epithelial Cells)*		250
	(Neisseria gonorrhoeae, DNA, Urine)*		250
	(Neisseria gonorrhoeae, DNA, Scrape of Urogenital Epithelial Cells)*		250
-			
	(Lactobacillus spp., DNA, Scrape of Urogenital Epithelial Cells)*		320
-			
	Clostridium difficile (Toxin A and B Clostridium difficile. One step rapid immunochromatographic assay)		1200
	(Clostridium difficile,) (Clostridium difficile Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		1250
? -			
	()		1000
	() (Cytological Examination: Cervix, Pap-test)		1000

IgE:			
/H1-Greer, IgE (House Dust – Greer, IgE, H1)			440
Penicillium notatum, IgE (Penicillium notatum, IgE, M1)			440
Candida albicans, IgE (Candida albicans, IgE, M5)			440
Dermatophagoides pteronyssinus (D1), IgE (Dermatophagoides pteronyssinus, IgE, D1)			440
Aspergillus fumigatus, IgE (Aspergillus fumigatus, IgE, M3)			440
Alternaria tenuis, IgE (Alternaria tenuis, IgE, M6)			440
Dermatophagoides farinae (D2), IgE (Dermatophagoides farinae, IgE, D2)			440
: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgE (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgE)*			950
Cladosporium herbarum, IgE (Cladosporium herbarum, IgE, M2)			440
IgG:			
Dermatophagoides farinae (D2), - IgG (Dermatophagoides farinae, IgG, D2)			520
/Greer (1), - IgG (House Dust – Greer, IgG, H1)			520
Cladosporium herbarum (2), - IgG (Cladosporium herbarum, IgG, M2)			520
: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgG (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgG)*			950
Penicillium notatum (1), - IgG (Penicillium notatum, IgG, M1)			520
Dermatophagoides microceras (D3), - IgG (Dermatophagoides microceras, IgG, D3)			520
Dermatophagoides pteronyssinus (D1), - IgG (Dermatophagoides pteronyssinus, IgG, D1)			520
Alternaria tenuis (6), - IgG (Alternaria tenuis, IgG, M6)			520
: (AZF-) (-) (Impairment of Spermatogenesis: Full Panel (AZF-Region) (without Description))			9290
: (F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) ((-) (Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (without Description))			15700
, CYP21A2, . . . (Gene CYP21OHB, Freq. Mut.)			9790
: (F2, F5) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5))			2730
(AR, CFTR; AZF-) (Genetic Factors of Male Infertility (Genes AR, CFTR; AZF-Region))			16420
(MTHFR, MTRR, MTR) (Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR))			5280
: (F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD))			18180
: (MTHFR, MTRR, MTR, F2, F5) (-) (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))			7180
(F2, F5) (-) (Thrombotic Complications of Ovulation Induction (Genes F2, F5) (without Description))			2450
(MTHFR, MTRR, MTR) (-) (Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR) (without Description))			4730
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5))			10610
(F2, F5) (Thrombotic Complications of Ovulation Induction (Genes F2, F5))			2730
: (F2, F5) (-) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5) (without Description))			2450

(MTHFR, MTRR, MTR, F2, F5) (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5))		8010
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (MTHFR, MTRR, MTR, F2, F5) (without Description))	(Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (without Description))	9440
(Hereditary Breast and/or Ovarian Cancer)	BRCA1, BRCA2, CHEK2, NBS1	9350
(Examination of Sputum)		750
Secrets)	(Examination of Transudates, Exudates,	480
Bronchial Washouts)	(Examination of	590
	(Examination of Punctates: Skin)	590
	(Examination of Endoscopic Material)	590
A08.20.004		600
Endoscopic Material: Presence of Helicobacter pylori)	Helicobacter pylori (Examination of	710
	(Cytological Examination of Material Obtained during Surgical Procedures and Other Urgent Research)	750
(ThinPrep ®)*	1200
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)		570
() (Cytological Examination: Scrapings (Smear) of Nasal Mucous Membrane (1 Localization))	(710
	(Examination of Breast Discharge)	480
Tissues)	(Examination of Punctates: Other Organs and	750
Device, IUD)	() (Examination of Imprint Intrauterine	510
	(Examination of Punctates: Breast)	590
of Scrapings and Prints Tumor and Tumor Like Formations)	(Examination	590
	(Examination of Urine)	480
	(The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), Fine-Needle Aspiration (FNA))	570
Scrapings and Prints of Skin and Mucous Membranes)	(Examination of	390
and Cervical Canal)	(Examination of Scrapings: Cervix	570
Ig	(nti-Measles IgM)	710
IgG	(nti-Measles IgG)	800
IgG)	IgG (Anti-Tick-borne Encephalitis Virus (TBEV)	480
	(Detection of pathogen DNA/RNA in ticks: Tick-borne encephalitis Virus (TBEV), Borrelia burgdorferi s. l., Anaplasma Phagocytophillum, Ehrlichia muris/chaffe nsis (RNA/DNA), PCR)	3360
IgM)	IgM (Anti-Tick-borne Encephalitis Virus (TBEV)	610
- -	() (HPLC-MS/MS Organic Acids (Succinylate))	3590

HADHA (3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) Deficiency)		5010
e « » (Newborn Screening "HEEL")*		4990
Carboxylases Activity (Biotinidase Deficiency)	(Biotin-Dependent)	5010
GCDH (Glutaryl-CoA Dehydrogenase) Gene, Freq. Mut. (Glutaric Aciduria, Type 1)	1) (GCDH (Glutaryl-CoA Dehydrogenase))	5010
(/) (Analysis of the spectrum of organic urine acids by gas chromatography with mass spectrometry (GC / MS))		8300
ASS (Citrullinemia)	(ASS Gene, Freq. Mut. (Citrullinemia))	9530
GCDH (Glutaric Aciduria, Type 1)	1) (GCDH (Glutaryl-CoA Dehydrogenase))	40400
ACADM (MCAD) Deficiency)	(ACADM Gene, Freq. Mut. (Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency))	5010
FAH (Tyrosinemia, Type 1)	(FAH Gene, Freq. Mut. (Tyrosinemia, Type 1))	8340
BTD (Biotinidase Deficiency) Gene, Freq. Mut.)	(BTD (Biotinidase Deficiency) Gene, Freq. Mut.)	5010
FAH (Tyrosinemia, Type 1)	(FAH Gene (Tyrosinemia, Type 1))	49900
Transcarbamylase (OTC) Deficiency)	(TC Gene (Ornithine Transcarbamylase (OTC) Deficiency))	38030
(, Escherichia coli)		
(Escherichia coli O157:H7,), (Escherichia coli O157:H7 Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		1100
(Escherichia coli O157:H7,), (Escherichia coli O157:H7 Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		930
(Escherichia coli O157:H7,), (Escherichia coli O157:H7. One Step Rapid Immun hromotographic Assay)		930
immunodeficiency virus, quality, RNA)	1, (Human)	2470
19,		330
- RHD (RHD gene of the fetus in the mother's blood)		5550
19,		330
19,		330
(Legionella pneumophila, One step rapid immun hromotographic assay, antigen, urinae)		1440
(Respiratory Syncytial Virus, RSV, One step rapid immun hromotographic assay, antigen)		930
(Hexagon Chlamydia, One step rapid immun hromotographic assay, antigen)		1020
(Neisseria gonorrhoeae test, One step rapid immun hromotographic assay)		860
(Campylobacter spp., One step rapid immun hromotographic assay, antigen, stool)		1040
(Norwalk virus) - (Norwalk virus GI , GII, One step rapid immun hromotographic assay, antigen, stool)		1750
(Streptococcus pneumoniae, One step rapid immun hromotographic assay, antigen, urinae)		1440
(Enterovirus, One step rapid immun hromotographic assay, antigen, stool)		1090
IgG -3 (Desmoglein 3, DSG3 Antibodies, IgG)		2160
IgG BP230 (Anti-Bp230 ntibodies, Bullous Pemphigoid (230 kDa) Antibodies, Antibodies to BP Antigen 1, IgG)		2160

IgG BP180 (Anti-Bp180 antibodies, Bullous Pemphigoid (180 kDa) Antibodies, Antibodies to BP Antigen 2, IgG)		2160
IgG (Desmoglein Antibodies, Desmoglein 1, DSG1 and Desmoglein 3, DSG3 Antibodies, IgG)		2160
, IgG (Basement membrane zone antibodies, IgG)		2020
IgG -1 (Desmoglein 1, DSG1 Antibodies, IgG)		2160
()		
A IgA Helicobacter pylori (Anti-Helicobacter pylori IgA)		700
A IgG Helicobacter pylori, (Anti-Helicobacter pylori IgG, Immunoblot)		3070
A IgA Helicobacter pylori, (Anti-Helicobacter pylori IgA, Immunoblot)		3070
A IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)		490
1303HEL ?? - Helicobacter pylori (?? - , 13C-Urea Breath test, UBT).		2180
A IgM Helicobacter pylori (Anti-Helicobacter pylori IgM)		700
()		
Sputum)* , (Mycobacterium tuberculosis, DNA, tuberculosis, DNA, Synovial Fluid)* (Mycobacterium tuberculosis, DNA, Cerebrospinal Fluid)* (Mycobacterium tuberculosis, DNA, Prostatic Fluid, Semen)* (Mycobacterium tuberculosis, DNA, Urine)* (Mycobacterium tuberculosis, DNA, Serum)* (Mycobacterium tuberculosis, DNA, Menstrual Blood)*		590 460 250 250 250 1630 250 390 250
() (Circulating Immune Complexes (CIC)		
Total)		1080
(Phagocytic Activity of Leucocytes)		1000
(Lymphocyte Activation Ability)		3450
CD4+ - , % (- , CD4+ T-cells, Percent and Absolute)		1370
(CD3+ HLA-DR+, CD3-HLA DR+)* (Activated Lymphocyte: CD3+ HLA-DR+, CD3-HLA DR+)*		1370
- , % (CD19+ , B-cells, Percent and Absolute)		1370
(Lymphocyte Phenotyping: CD3, CD4, CD8, CD19, CD16, CD56)		3450
G (IgG1, IgG2, IgG3, IgG4)		12510
()		
Virus IgM, Anti-VZV IgM (Anti-Varicella-Zoster Virus IgM, Anti-VZV IgM)		780
Varicella-Zoster, (Varicella ZosterVirus, DNA, serum)		360
Virus IgG, Anti-VZV IgG (Anti-Varicella-Zoster Virus IgG, Anti-VZV IgG)		710
Varicella-Zoster, (Varicella Zoster Virus, DNA, scrape of faucial epithelial cells)		360
Varicella-Zoster, (VaricellaZosterVirus, DNA, saliva)		360
()		
(Stool Culture, Salmonella s p., Shigella s p. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		1150

Shigella flexneri 1-5 (Shigella flexneri 1-5, IHA)	440
Identification) (Stool Culture (Salmonella spp., Shigella spp.). Bacteria	780
Shigella sonnei (Shigella sonnei, IHA)	440
(Stool Culture (Salmonella spp., Shigella spp.). Bacteria Identification and Antibiotic Susceptibility Testing)	970
Shigella flexneri 6 (Shigella flexneri 6, IHA)	440
HER2/neu , HER2-) (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	4990
: - - - (P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)*	11400
() :) (Immunohistochemical diagnosis of lymphoproliferative diseases (Tissue Embedded in Paraffin Block))	25280
Ki-67 (MIB-1) , Ki-67 () (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*	5090
(CD138) () (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Paraffin Block))	5000
() :) (Immunohistochemical diagnosis of lymphoproliferative diseases (Fixed Biomaterial in Formalin Buffer))*	25280
() (Estrogen and Progesterone Receptors, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	7140
: p16INK4a () (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	4430
() :) (Immunohistochemical diagnosis in cancer metastasis of unknown primary origin (Tissue Embedded in Paraffin Block))	25280
Progesterone Receptors, Immunohistochemical Study)* (Estrogen and	6410
: - - - (P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)	11400
: p16INK4a () (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*	4430
HER2 in situ (FISH) (Determination of HER2 Status of Tumor, Fluorescence In Situ Hybridization)	29660
Ki-67 (MIB-1) , Ki-67 () (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	5090
(CD138) () (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Formalin Buffer))*	5000
HER2/neu , HER2-) (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*	4990

Antibodies Pool, Glutamic Acid Decarboxylase-65, GAD and Insulinoma Antigen 2 (Tyrosine Phosphatase, IA2, ICA-512) Autoantibodies, Total)	GAD/IA-2, (Anti-GAD/IA2	1550
IgG (-GAD) (Anti-GAD Antibodies, Glutamate Decarboxylase Antibodies, AT-GAD, IgG)		1590
(,)		
(Yersinia enterocolitica, (Yersinia enterocolitica, Stool Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		1240
Yersinia enterocolitica :9 (Yersinia enterocolitica O:9, IHA)		440
IgG Yersinia enterocolitica (Anti-Yersinia enterocolitica IgG)		490
IgA Yersinia enterocolitica (Anti-Yersinia enterocolitica IgA)		490
Yersinia enterocolitica :3 (Yersinia enterocolitica O:3, IHA)		440
Yersinia pseudotuberculosis (Yersinia pseudotuberculosis IHA)		440
(F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1))		
(ITGB3) ((Platelet Fibrinogen Receptor (Gene ITGB3) (without Description))		1260
: (F2, F5, MTHFR, MTRR, MTR) ((Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR) (without Description))		7180
ITGA2 .759 >T Hyperaggregation of platelets, gene polymorphism ITGA2 .759 >T		2760
: (F2, F5) ((Thrombosis: Minimum (Genes F2, F5) (without Description))		2450
(MTHFR, MTRR, MTR) ((Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR) (without Description))		4730
-) Hyperaggregation of platelets, gene polymorphism ITGA2 .759 >T (without description)		2470
: (F2, F5) (Thrombosis: Minimum (Genes F2, F5))		2730
(MTHFR, MTRR, MTR) (Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR))		5280
: (F2, F5, MTHFR, MTRR, MTR) (Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR))		8010
(F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) ((Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (without Description))		9450
(Listeria monocytogenes, DNA, Cerebrospinal Fluid)*		
(Listeria monocytogenes, DNA, Urine)*		230
(Listeria monocytogenes, DNA, Scrape of Nasal Epithelial Cells)*		210
(Listeria monocytogenes) (Listeria monocytogenes Culture. Bacteria Identification and Antibiotic Susceptibility testing)		690
(Listeria monocytogenes, DNA, Plasma)*		210
(Listeria monocytogenes, DNA, Scrape of Faucial Epithelial Cells)*		210
(Listeria monocytogenes, DNA, Synovial Fluid)*		460
IgE:		
: , IgE (GP3 (G1, G5, G6, G12, G13), Grass Panel: Sweet Vernal Grass, Perennial Rye Grass, Timothy Grass, Cultivated Rye Grass, Velvet Grass, IgE)*		950
, IgE (Cottonwood, IgE, T14)		440
, IgE (Wormwood, IgE, W5)		440
, IgE (Timothy Grass, IgE, G6)		440

		IgE (WP1 (W1, W6, W9, W10, W11), Weed Panel: Common Ragweed, Mugwort, English Plantain, Lamb's Quarters, Russian Thistle, IgE)*	950
		IgE (Birch, IgE, 3)	440
		IgE (Mugwort, IgE, W6)	440
		IgE (TP9 (T2, T4, T12, T3, T7), Tree Panel: Alder, Hazelnut, Willow, Birch, Oak, IgE)*	950
		IgE (GP1 (G3, G4, G5, G6, G8), Grass Panel 1: Orchard Grass, Meadow Fescue, Perennial Rye Grass, Timothy Grass, June Grass (Kentucky Bluegrass), IgE)*	950
25-OH	D	(25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)	1920
		(Deoxy pyridinoline, DPD, Urine)	1250
		(osteocalcin, N-Osteocalcin, Bone Gla Protein, BGP)	670
N-P1NP, Total)	1	(Procollagen Type 1 N-terminal Propeptide,	1360
		(Carboxyterminal Cross-linking Telopeptide of Bone Collagen, Collagen Cross-linked C-Telopeptide, Beta-Cross Laps, ?-CrossLaps Serum, C-Telopeptide, Crosslaps, Type 1 Collagen, b- Tx Serum)	870
		(Human Cartilage Oligomeric Protein, COMP)	2450
		(A B)	
		(Streptococcus group B, Streptococcus agalactiae), (Streptococcus agalactiae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	880
		(Streptococcus group B, Streptococcus agalactiae) (Streptococcus agalactiae Culture. Bacteria Identification)	690
		(Streptococcus Group B. One Step Rapid Immun chromatographic Assay)	1050
		(Streptococcus Group A. One Step Rapid Immun chromatographic Assay)	870
		(Streptococcus group A, Streptococcus pyogenes), (Streptococcus pyogenes Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	810
		(Streptococcus spp., DNA, Saliva)*	390
		(Streptococcus group A, Streptococcus pyogenes) (Streptococcus pyogenes Culture. Bacteria Identification)	620
		(Streptococcus spp., DNA, Plasma)*	590
		(Streptococcus spp., DNA, Scrape of Faucial Epithelial Cells)*	390
		(Streptococcus spp., DNA, Sputum)*	790
A09.28.034.001		(Metanephrines fractionated, free and conjugated , 24-h urine)	2260
24-		(Catecholamines and Serotonin Metabolites, 24 Hours-Urine: Vanillylmandelic Acid, V , Homovanillic Acid, V , 5-Hydroxyindoleacetic Acid, 5- I)	2260
		(Serotonin, Serum)	2090
		(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)	2060
		(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Plasma)	2090
		(Histamine, Plasma)	2420
		(Metanephrines fractionated, free + conjugated, random urine)	1830
		(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)	2060
		(Opisthorchis felineus)	
		(Anti-Opisthorchis felineus IgG)	790

(Giardia lamblia), Rapid Immunochromatographic Assay)	(Giardia lamblia. One Step	870
IgM, IgG, IgA (IgA, Total)	(Anti-Giardia lamblia IgM, IgG,	570
()		
A09.28.027) (Amylase, 24-Hour or Timed Urine)	(- ,	230
(Ca), (Calcium (Ca), 24-Hour urine)		200
(K), (Na), (Potassium (K), Sodium (Na), 24-Hour urine)		190
((Glomerular Filtration Rate, GFR)*)	190
A09.28.011 , (Glucose, 24-Hour urine)		150
A09.28.009 , (Urea, 24-Hour urine)		150
A09.28.010 , (Uric acid, 24-Hour urine)		190
A09.28.003 , (Protein Total, 24-Hour urine)		130
, (), (Magnesium, 24 h urine excretion)	300
		1890
, (oxalates, 24-Hour urine)		1220
A09.28.003.001 , (Albumin, 24-Hour urine)		320
A09.28.006 , (Creatinine, 24-Hour urine)		150
(P), (Phosphorus (P), 24-Hour urine)		200
A09.05.054.002 (Immunoglobulin A, IgA)		250
A09.05.054.003 (Immunoglobulin , Ig)		250
A09.05.054.004 G (Immunoglobulin G, IgG)		250
A09.05.054.001 (Immunoglobulin Total, IgE Total)	E (IgE,)	390
IgG Membrane antibodies, anti-GBM, IgG)	(-) (Glomerular Basement	1560
IgG antibodies, ANCA, IgG)	() (Anti-Neutrophil cytoplasmic	1220
IgG PR-3 ANCA, IgG)	-3 (-PR-3) (Anti- proteinase-3 antibodies, PR-3- antibodies,	1120
IgG, IgA, IgM (Anti-Phospholipase A2 Receptor Antibodies, Anti-PLA2R, IgG, IgA, IgM, Total)	2 (PLA2R),	2470
(Anti-Neutrophil Cytoplasmic Antibodies, ANCA, IgG, Panel)	() , IgG	3100
IgG C1q (Anti-Complement 1q Antibodies, Anti-C1q,		1120
IgG, IgA, IgM (Anti-Endothelial Cell Antibodies, AECA, IgG, IgA, IgM, Total)	(HUVEC),	1550
IgG (- PO) (Myeloperoxidase Antibody, MPO)		1120
1- 3- (Anti-Poliovirus serotypes 1, 3, IgG)		1450
b, IgG (IgG (HiB), anti-PRP Haemophilus influenzae b IgG)	(polyribosylribitolphosphate, PRP) (Haemophilus influenzae b	1810
()		
A IgG Borrelia burgdorferi (Anti-Borrelia burgdorferi IgG)		570
Cerebrospinal Fluid)*	(orrelia burgdorferi, DNA,	460
Fluid)*	(orrelia burgdorferi, DNA, Synovial	460
A IgM Borrelia burgdorferi, burgdorferi IgM, Western Blot (WB))	- (Anti-Borrelia	1800
A IgG Borrelia burgdorferi, (Anti-Borrelia burgdorferi IgG, Immunoblot)		2020

A	IgM Borrelia burgdorferi (Anti-Borrelia burgdorferi IgM)	570
(Barbiturates, Urine)*		
	() (Drugs and Psychotropic Substances Screening: Opiates, Amphetamines, Methamphetamine, Cocaine, Cannabinoids, Cannabinoid Metabolites, Urine)	1120
	() (Cannabinoids (Marijuana), Urine)*	3100
	() (Ethanol (Alcohol) Urine)*	1120
« » () (;) (Pernicious Habits: Nicotine, Drugs, Psychostimulants and Psychotropic Substances, Urine)*		1120
	(/) (Opiates (Morphine/Heroin), Urine)*	3280
- (-)		
	(EBV DNA, Exudate)*	1120
Fluid)*	(EBV DNA, Cerebrospinal Fluid)*	250
IgG Antigen (VCA) IgG)	- (nti-EBV Viral Capsid	250
IgG)	- (nti-EBV Early Antigen (EA	690
(EBNA) IgG)	- (nti-EBV Nuclear Antigen	570
	(EBV DNA, Blood)*	480
	(EBV DNA, Saliva)*	380
Fluid, Semen)*	(EBV DNA, Prostatic	250
	(EBV DNA, Scrape of Nasal Epithelial Cells)*	250
	(EBV DNA, Scrape of Urogenital Epithelial Cells)*	250
Ig Antigen (VCA) Ig)	- (nti-EBV Viral Capsid	480
DNA, Scrape of Faucial Epithelial Cells)*	(EBV	250
Serum)*	(EBV DNA,	370
	(EBV DNA, Urine)*	250
	(EBV DNA, Serum)*	380
IgE:		
	2	1840
	, IgE (Pediatric Panel, IgE)	3670
	1	1840
	, IgE (Respiratory Panel, IgE)	3670
	, IgE (Panel Different Allergens, IgE)	3670
ImmunoCAP ISAC, 112 Allergic components)	(Allergochip ImmunoCAP ISAC, 112	27300
ALEX2, 300	IgE	26990
(MTHFR, MTRR, MTR) (
-) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR) (without Description))		4730
: D (VDR) ((Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR) (without Description))	1260
((MCM6) (Adult Lactase Deficiency (Gene MCM6)	1310
, I (HFE) (Hemochromatosis Type 1 (Gene HFE))		2600
: D (VDR) (Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR))		1390

(UGT1A1) (Gilbert's Syndrome (Gene UGT1A1))		4540
: (CALCR, COL1A1) (3630
-) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1) (without Description))		5280
(MTHFR, MTRR, MTR) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR))		4050
: (CALCR, COL1A1) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1))		4730
- (CALCR, COL1A1, VDR) (6240
) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR) (without Description))		5280
1-		
HLA II (DRB1, DQA1, DQB1) (Hereditary Predisposition to Diabetes Type 1 (Insulin-Dependent Diabetes), HLA Class II (Genes DRB1, DQA1, DQB1))		
: (CALCR, COL1A1, VDR) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR))		
-		
2 (118 / , 121 / , 123 / , 131 / , 141 / , 115 / , 124 / , 154 /) (Genetic Test Results: Description of the 2-nd Category Complexity)		1050
1 (7201 , 7611 , 7014 , 125 / , 7207) (Genetic Test Results: Description of the 1-st Category Complexity)		530
3 (122 / , 129 / , 120 / , 137 / , 138 / , 153 / , 110 / , 114 / , 140 / , 7661 , 7258 , 134 / , 135 / , 136 /) (Genetic Test Results: Description of the 3-rd Category Complexity)		2100
4 (144 / , 143 / , 139 / , 145 / , 108 / , 19 /) (Genetic Test Results: Description of the 4-th Category Complexity)		4730
(4)		
(Isoprinosine)		490
(Immunomax)		490
(Immunal)		490
(Thymogen)		490
(Panavir)		490
(Tactivinum)		490
(Imunofan)		490
(Polyoxidonium)		490
(Galavit)		490
(Imunorix)		490
(Licopid)		490
()		
IgG oxoplasma gondii (nti-Toxoplasma gondii IgG)		360
Ig oxoplasma gondii (nti-Toxoplasma gondii Ig)		490
, (Toxoplasma gondii, DNA, Serum)*		380
, (Toxoplasma gondii, DNA, Cerebrospinal Fluid)*		250
Anti-Toxopl gondii IgG		950
, (Toxoplasma gondii, DNA, Exudate)*		250
(Streptococcus pneumoniae)		450
(Bordetella pertussis/parapertussis, /) (Bordetella pertussis/parapertussis, Nasopharyngeal Culture. Bacteria Identification)		1440
(2) (Estradiol, E2)		350
(Progesterone)		350

A09.05.135	() (Cortisol, Hydrocortisone)	350
A09.28.035	(Free Cortisol, Free Hydrocortisone, 24-Hour urine)	690
A09.05.069	(Aldosterone)	780
A09.05.121	() (Direct Renin, Plasma)	830
	(Cortisol, Saliva)	560
A09.05.230	(Cystatin C)	680
A09.05.017		150
A09.05.018	(Uric acid)	150
A09.05.020		150
-	p16INK4a Ki-67	5500
	(PLGF)	3600
	(Inhibin B)	1120
MIS)	() (Anti-Mullerian Hormone, AMH, Mullerian Inhibiting Substance,	1120
	-1- () (Trophoblastic beta-1-Globulin, TBG)	440
	IgG V (Annexin V antibodies, aAnV, IgG)	1190
	Ig V (Annexin V antibodies, aAnV, Ig)	1190
	IgG, IgA, IgM -2- 1, (Anti-?-Glycoprotein 1 Antibodies, anti-?-G 1, IgG, IgA, IgM, Total)	1140
	IgM IgG (Anti-Phospholipid Antibodies, APA, IgM, IgG)	730
	2 IgA	1090
	IgG IgM - (Anti- phosphatidylserine/ rothrombin antibodies, Anti-PS/PT, IgG, IgM, Total)	1220
	IgA, IgM, IgG (Cardiolipin Antibodies IgA, IgM, IgG, aCL, Screening)	1030
	IgG IgM (Anti- phosphatidylserine, IgG, IgM)	1620
	2 IgM	1190
	, IgG, IgM - (Anti-Phospholipid Antibodies Panel)	8190
	IgA (Anticardiolipin IgA, aCL IgA)	760
	2 IgG	1090
	IgG (Anticardiolipin IgG, aCL IgG)	820
	IgM (Anticardiolipin IgM, aCL IgM)	1080
	(Bile Acids)	2410
	1 (1, 1) (Apolipoprotein A1, Apo A1)	520
	(, , VLDL)	370
	B (B,) (Apolipoprotein B, Apo B)	390
A09.05.025	() (Triglycerides)	190
A09.05.004		200
	(a), () (Lipoprotein (a), Lp (a))	790
A09.05.028		150
A09.05.026	() (Cholesterol Total)	190

() Cholesterol LDL (direct)		230
(4)		
(Neovir)		490
(Amixin)		490
(Cycloferonum)		490
(Kagocel)		490
,		
Protein-A, PAPP-A	(Pregnancy-Associated Plasma	630
A09.05.090 Gonadotropin, HCG	(, - , ?-) (Human Chorionic	350
?- (?-) (Free	Human Chorionic Gonadotropin, Free HCG)	490
PRISCA2		90
fms- -1 (sFlt-1)		3070
(Estriol Free, 3)		440
PRISCA1		120
Placental Lactogen, hPL, Chorionic Somatomammotropin, CS, Human Chorionic Somatomammotropin, hCS)	() (Placental Lactogen, PL, Human	630
,		
() (Erythrocyte Sedimentation Rate, ESR)		130
« » (Leucocyte Formula (Differential White Blood Cell Count) with Manual Microscopic Examination of Blood Smear)*		300
(Leucocyte Formula (Differential White Blood Cell Count) with Microscopic Examination of Blood Smear if Presence of Pathologic Changes)*		190
Microscopy (Manual Platelet Count (PLT Count): Indirect Method by Fonio)*	(Platelets,	250
without White Blood Cell (WBC) Count and ESR)	() (General Blood Analysis,	190
A12.05.123 (Reticulocytes)		240
		1800
(4)		
(Ingaron)		490
(Reaferonum)		490
,		
Bordetella species: Bordetella pertussis () Bordetella bronchiseptica ()	(Differentiated detection of DNA Bordetella spp.: Bordetella pertussis (pertussis pathogen) and Bordetella bronchiseptica (bronchosepticosis pathogen) in a scraping of the oropharynx and or nasopharynx)	840
A IgG Bordetella pertussis (Anti-Bordetella pertussis IgG)		810
A IgM Bordetella pertussis (Anti-Bordetella pertussis IgM)		810
A IgA Bordetella pertussis (Anti-Bordetella pertussis IgA)		810
,		
-3 (Omega-3 Index)		4340
(Procalcitonin)		2730
, : -3,-6,-9, (Fatty acids panel, omega-3, -6, -9, plasma)		8340
,		
Rh- (Anti Rh)		470
A12.05.005 (Blood Group, 0)		230

Rh (C, E, c, e) Kell-	(Rh C (E, c, e) Kell-Phenotyping)	600
A12.05.006 -	(-) (Rh-factor, Rh)	230
: Assessment)*	(Water: Complete and Comprehensive Quality	18180
: Contamination)*	(Water: Suspicion Industrial Waste	12900
: (Water: Suspicion Products of Combustion and Emissions from Motorways Contamination)*		9530
: Contamination)*	(Water: Suspicion Household Waste	8130
: (Water: Abridged Quality Assessment)*		8790
: Excessive Use of Chemicals for Water Treatment)*	(Water: Suspicion	4690
(, <i>Trichinella spiralis</i>)		
IgG	(nti-Trichinella IgG)	470
: 20	(Water: Quality Assessment 20 Parameters)*	3730
: Radionuclides)*	6 (Determination of Concentration 6	22430
?- (Radiological Drinking Water Study – Basic Test ?- and ?-Activity)*	- ?-	6170
: 30	(Water: Quality Assessment 30 Parameters)*	7060
: Radionuclides)*	4 (Determination of Concentration 4	14940
Panel (Genes ACE, AGT, NOS3)	(ACE, AGT, NOS3) (Arterial Hypertension: Full	4140
- Description))	(ACE, AGT, NOS3) (3710
ACE, AGT) (Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT))	(2760
ACE, AGT) (-) (Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT) (without Description))	(2470
(NOS3) (-) (Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3) (without Description))	NO-	1260
()	(Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry)	3520
()	(Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry, -ray diffraction analysis)	3520
	(Alzheimer's Disease)	2600
Gastrin-17, G-17)	- -17 () (Gastrin-17 Stimulation Test,	1100
I (Pepsinogen I)		880
A09.05.057 (Gastrin)		620
(GastroPanel)		4160
II (Pepsinogen II)		880
G	(G, Hepatitis G Virus, HGV)	
G,	(HGV RNA, Serum)*	600
(FibroTest)		10860

(FibroMax)		13880
(FibroTest)		12200
(SteatoScreen)		5760
(FibroMax)		16000
NASH-FibroTest		17550
NASH-FibroTest ()		17120
()		7200
() (Karyotype)		7090
()		16170
(Acute Intestinal Infections, PCR, Fecal)		1430
(Enterovirus, RNA, Fecal)		470
(Acute Intestinal Infections, PCR, Fecal)		1130
CYP2D6 (beta-Adrenergic Blockers. Gene CYP2D6)		7390
ATII.		2760
(ACE) (ACE Inhibitors, Fluvastatin, ATII Receptor Blockers.		5280
(Methotrexatum. Genetic Markers of Increased Risk of Development of Adverse Reactions in Taking Methotrexate for Treatment of Rheumatoid Arthritis. Methotrexate Disrupts Metabolism		
A IgG (Anti-Mumps IgG)		710
A IgM (Anti-Mumps IgM)		710
()		450
(Streptococcus pneumoniae, DNA)		
(Calcitonin)		860
A09.05.058 () (Parathyroid Hormone, PTH)		610
(, Echinococcus spp.)		790
IgG (Anti-Echinococcus IgG)		
IgG (Anti-Entamoeba histolytica IgG)		630
D (D, Hepatitis D Virus, HDV)		780
IgM IgG D, o (Anti-HDV Total (IgG + IgM))		600
D, (HDV RNA, Serum)*		780
IgM D (nti-HDV IgM)		
Aspergillus fumigatus (3), - IgG (Aspergillus fumigatus, IgG, M3)		520
(Bacteroides spp., DNA, Scrape of Urogenital Epithelial Cells)*		210

A (, Hepatitis A Virus, HAV)			
IgG	(Anti-HAV IgG)		510
	(HAV RNA, Serum)*		590
IgM	(Anti-HAV IgM)		730
()			
(Gardnerella vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*			250
Prostatic Fluid, Semen)*		(Gardnerella vaginalis, DNA,	250
		(Gardnerella vaginalis, DNA, Urine)*	250
Converting Enzyme, ACE, Serum)		() (Angiotensin	2200
() (Neopterin, Serum)			1550
IgG (Anti-Heart Antibodies, IgG)		() ,	1220
HOMA-G	()		50
HOMA-IR			50
A09.05.056.001	(Proinsulin)		830
-	(C-Peptide)		390
A09.05.056	(Insulin)		490
Identification)		(Campylobacter s p.) (Campylobacter spp., Stool Culture. Bacterial	1240
()			
(Rotavirus), Agglutination)		(Rotavirus Direct Detection by Latex	680
			3690
- (Varicella-Zoster)			
Varicella-Zoster, Zoster Virus, DNA, scrape of skin epithelial cells)		(Varicella	360
(-)			
		(Fungal Infections of Nails)	820
		(Fungal Infections of Skin)	820
IgG		(Platelet antibodies IgG, Indirect)	2980
(, , Salmonella spp.)			
Salmonella gr.A (Salmonella gr.A, IHA)			440
Salmonella gr.B (Salmonella gr.B, IHA)			440
Salmonella gr.E, (Salmonella gr.E Antibodies, IHA)			440
Salmonella typhi, (Salmonella typhi Antibodies, IHA)			560
Salmonella O- (Salmonella O-antigens, IHA)			440
Salmonella gr.D (Salmonella gr.D, IHA)			440
Salmonella gr. (Salmonella gr.C, IHA)			440
IgG		(Anti-Strongyloides stercoralis IgG)	900
()			
		(Rickettsia prowazekii, IHA)	440

A09.05.021			150
A09.05.022			150
Anisakis IgG			
()			740
IgG	(Anti-Diphtheria Toxoid IgG)		900
(Corynebacterium diphtheriae Culture)			690
(Anti-Spermatozoa Antibodies, ASA, Semen)			
	(Anti-Spermatozoa Antibodies, ASA, Serum)		1290
			950
(E, Hepatitis E Virus, HEV)			
IgM	E (Anti-HEV IgM)		810
IgG	E (Anti-HEV IgG)		810
IgG:			
(2), -	IgG (Dog Epithelium, IgG, E2)		520
(1), -	IgG (Cat Dander-Epithelium, IgG, E1)		520
(Streptococcus pneumoniae, DNA)			
IgG	(Anti-Adenovirus IgG)		710
IgA	(Anti-Adenovirus IgA)		710
(Streptococcus pneumoniae, DNA)			
(, Toxocara canis)			450
IgG	(Anti-Toxocara IgG)		470
(Androflor® REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)			
	(Androflor® Screen REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)		2580
			1810
(DLG5, NOD2, OCTN1, OCTN2) (Crohn's Disease (Genes DLG5, NOD2, OCTN1, OCTN2))			
IgA, IgM, IgG	(Anti-Ovarian Antibodies, AOA, IgA, IgM, IgG, Total)		8090
IgA, IgM, IgG	(Anti-Steroidal Cell Antibodies, StCAb, Steroidal Cell Autoantibodies, SCA, IgA, IgM, IgG, Total)		1290
IgA, IgM, IgG	(Anti-Testicular Steroid-ell Antibodies, Testicular Anti-Steroidal Cell Antibodies, Testicular StCAb, Steroidal Cell Autoantibodies, SCA against Testis, IgA, IgM, IgG, Total)		1120
			1550
YP2D6 (YP2D6) (Cytochrome YP2D6 (Gene YP2D6))			
(Neisseria meningitidis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)			
			7390
			850

() (Total Antioxidant Status, TAS)	4770
IgE:	
, IgE (Latex, IgG, K82)	440
IgG (Anti-Ascaris lumbricoides IgG)	880
(, Demodex folliculorum, Demodex brevis)	
(Demodex folliculorum, Demodex brevis)	340
Cytological Preparations (1 Glass) () (Consultation of Finished	380
Clonorchis sinensis IgG	980
- 8	
IgG 8 (Anti-HHV-8 IgG)	700
).* (Provision of test findings in English (translation of test findings in English)).*	200
(Erythropoetin)	960
(Leptin)	760
(Cryptosporidium parvum), (Cryptosporidium parvum. One Step Rapid Immun hromotographic Assay)	790
-	
IgG - 1 2 (Anti-HTLV-1, 2 IgG	780
(Study of Interferon Status)	2450
(Assessment of Androgen Status)	1460
: (Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)	3300
: (Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)	3420
:	3190
:	3520
:	6410
« »	7500
« »	9060
« »	15710
-	19010
() (Acute Respiratory Infections, ARI: Runny Nose, Cough, Sore Throat)	7390
A IgA IgG Chlamydia trachomatis, (Anti-Chlamydia trachomatis IgA, IgG)	970
« : 6 () » (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3150
« : 6 () » (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3270
: (Joint Pain: Extended Survey)	6780
	6990

:(Want to Become a Mother: Pregnancy Planning, Comprehensive Survey)	7240
VIP- (VIP-Survey for Men)	14790
VIP- (VIP-Survey for Women)	15700
(Pediatric Infections: Immune Response)	5440
A IgM IgG Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM, IgG)	990
TORCH- (ToRCH-Infections)	3240
: I (1-13) (Pregnancy: First Trimester (1-13 Weeks))	7480
, , (HIV, Syphilis, Hepatitis B, C)	1400
« : 8 + » (Comprehensive Study «Sex in City: 8 Infections + Smear on Flora»)	2540
: III (29-30) (Pregnancy: Third Trimester (29-30 Weeks))	3630
« : 14 + » (Comprehensive Study «Sex in City: 14 Infections + Smear on Flora»)	4010
:	9930
() (Hemostasiogram (coagulogram), extended	2510
: (Survey of Liver: Extended)	2630
(Hospitalization in Therapeutic Hospital)	3330
(Hospitalization in Surgical Hospital)	4600
: (Hospitalization in Surgical Hospital: Extended Survey)	6720
« » (My Healthy Nurse)	7020
ROMA (Risk of Ovarian Malignancy Algorithm,) () (Risk of Ovarian Malignancy Algorithm, ROMA (Before Menopause))	1650
ROMA (Risk of Ovarian Malignancy Algorithm,) () (Risk of Ovarian Malignancy Algorithm, ROMA (After Menopause))	1650
- () (Breast Cancer, Immunohistochemistry, IHC (Formalin-Fixed Biomaterial))	15660
- () (Breast Cancer, Immunohistochemistry, IHC (Paraffin-Embedded Tissue Block))	15660
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Paraffin Block))	7830
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Formalin Buffer))*	7830
: (Metabolic bone and osteoporosis risk evaluation: comprehensive examination).	5360
: I (PRIS A-1) (Maternal Screen, First Trimester; Prenatal Screening I; PRIS A I (Prenatal Risk Calculation))	1170
: II (PRIS A-2) (Maternal Screen, Second Trimester; Prenatal Screening II; PRISCA II (Prenatal Risk Calculation))	1300
B03.005.006 (), (Coagulation, Gemostaziogram, Screening)	770
: (Miscarriage: Autoimmune Profile)	3640
(Immunological Survey Extended)	10980
: (Survey of Liver: Screening)	840
B03.016.004 :	1100
Supersport	2000
: (Serum Biochemistry: Minimum)	2020
Supersport	3100

	(Serum Biochemistry: Extended Profile)	3230
	(40) (Healthy	3510
You ? Healthy Country: Annual Check-Up up to 40 Years of Age)	(40) (Annual Check-Up after 40 Years of	4480
Age)	(Survey Before Diet: Additional)	4690
Supersport		6830
		3690
	(Survey of Kidneys: Extended)	2000
	(Diabetes Control: Extended)	3220
	(Toxic Trace Elements, Hair)	1620
	(Toxic Trace Elements, Essential Vital	3090
Elements, Hair)	(Elemental Composition of Hair: Screening)	5400
	(Essential Vital	2600
Elements, Toxic Trace Elements, Urine)	(Toxic Trace Elements, Nails)	1620
	(Toxic Trace Elements, Essential Vital	3090
Elements, Nails)	(Elemental Composition of Nails: Screening)	5400
		24050
		24050
		24050
		24050
		24050
		33000
	(Testing for Kindergarten and School)	1580
	0 14 (Healthy Child: for Children from 0 to 14 Years)	660
	(Survey of Kidneys: Screening)	870
		890
		18500
		17400
		17400
	(Panel Chronic myelogenous leukemia, CML)	11900
		33000
		11100
		3150
		2210
	(, ())	2160
	(2160
	(, (),	2250
(/pANCA, cANCA), IgG)	(, , IgG, IgM)	2890
	(, (),	3730
IgG)	(/pANCA, cANCA),	
	(, IgG;	3950
, Ig ; ()	(;	3970
, IgG, IgM; -2- 1)	(;	4620
: (Arthralgia: screening test)		6380
	(Autoimmune Liver Disease: Screening)	

(Rheumatic arthritises)	1670
SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
«)» (Bullous Dermatositis Diagnostics profile (antibodies to epidermis desmosomes, antibodies to skin basal membrane))	3970
SARS-CoV-2, IgM IgG (Abbott)	1290
SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
: (Thyroid Gland: Extended Survey)	1690
: (Thyroid Gland: Extended Survey)	1760
: (Thyroid Gland: Screening)	1010
: (Diabetes: Autoimmune Markers)	3560
(Rheumatoid arthritis).	2810
Ig IgG Mycoplasma hominis (nti-Mycoplasma hominis Ig , IgG)	830
, (/pANCA, cANCA), IgG)	2640
;)	2730
4 «)» (Systemic lupus erythematosus (SLE) profile, activity monitoring (anti-double-stranded DNA IgG, C3 and C4 complement components))	1220
, IgG; IgA) (, IgA;	1970
Intolerance) : () (Coeliac Disease: Gluten	5660
, IgG, IgM	1800
APS) (), (Antiphospholipid Syndrome,	3570
cANCA, IgG; /ANCA, IgA; ASCA, IgG, IgA) () (/pANCA,	4340
((),)	2470
IgA, IgG; IgA) (, IgA;	3230
steroid-producing cells Antibodies) (Reproductive tissue	2690
(Food Allergy)	8150
: (Lipid Profile: Extended)	2640
: (Lipid Profile: Extended)	2640
" / " IgE, ImmunoCAP	4510
" " IgE, ImmunoCAP	4510
(NOS3) (Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3))	1390
" / " IgE, ImmunoCAP	4510
)» (Comprehensive Study «Sex in City: 12 Infections (Urogenital Scraping)»)	2630
	1290
-	1460
*	4100
	11760
,	720
(Diagnosis of Anemia)	2890
(Diagnosis of Anemia)	3200
(Preventing Heart and Blood	2820
Vessel Diseases)	

Diagnosis of Urogenital Tract Infection (UTI))	(Pregnancy Planning:	2260
(Diabetes Control: Screening)		560
(Survey Before Diet: Minimum)		1560
(Problems: Primary Survey)) (Weight	2930
(Healthy skin beauty)		1260
HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)		670
(Problems: Metabolic Syndrome (Primary Identification, Screening)	(Weight	860
(Diagnosis of Osteoporosis)		2770
(Women's Oncorisk: Cervix)		1800
(Allergy to Animals, Dust, Mold)		5780
(Strong hair and nails, velvet skin)		3150
Venous Blood: Screening)	(Trace Elements, Serum,	3070
(Mold Allergy)		2010
(Plant Allergy)		4380
(Immunological Survey, Screening)		6400
(AR, CFTR; AZF- ;) (Male Sterility (Genes AR, CFTR; AZF-Region; Karyotype))		21360
(F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD, HLA II;) (Female Infertility, Pregnancy Complication (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD, HLA II; Karyotype))		25940
(e) (Toxic Trace Elements, Toxic		1250
(2150
(2040
		160
Filtration Rate, eGFR, CKD-EPI Creatinine Equation)	CKD-EPI – (Estimated Glomerular	160
B03.016.003 (420
: II (14-28) (Pregnancy: Second Trimester (14-28 Weeks))		760
(Clinical Blood Analysis: General Blood Analysis, Leucocyte Formula, ESR (with Manual Microscopic Examination of Blood Smear))	(« »	590
(Essential Vital Elements, Essential Trace Elements, Serum)		1250
disorders (6 AZF))	, 6 (AZF) (Spermatogenesis	4610
Spermatogenesis: Full Panel (AZF-Region))	(AZF-) (Impairment of	10370
IgG (:	5300
(DQA1, DQB1)	HLA II	6240
(RH factor Genotype)		9910
(skin))	() (Parasitic Fungi, Microscopy and Culture	1570

(nails)	() (Parasitic Fungi, Microscopy and Culture	1570
I II I/Pepsinogen II, PG1/PG2)	(I/ II) (Pepsinogen	1820
	: sFlt-1, PIGF, sFlt-1/PIGF	5880
	(Mycoplasma hominis Culture, Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1350
	(Male oncologic risk: prostate)	870
A09.05.120.001	(Aldosterone-Renin Ratio, ARR)	1280
	3, 4 (Complement components C3, C4)	720
"	", IgE, ImmunoCAP	2120
B03.016.005	(Lipid Profile: Screening)	700
	(ITGB3) (Platelet Fibrinogen Receptor (Gene ITGB3))	1390
	(Lipid Profile: Screening)	700
	CKD-EPI – (Estimated Glomerular Filtration Rate, eGFR, CKD-EPI ystatin C Equation)	720
	TREC KREC	4830
19.1	29 28.01.2021 . . .	10500
() . 5.1; .5.2; . 19.1	29 28.01.2021 .	15000
(, 40) . 5.1; .5.2; . 19.1	29 28.01.2021 .	12070
(, 40) . 5.1; .5.2; . 19.1	29 28.01.2021 .	11570
/		2000
		4800
		6800